Targeted Cancer Therapy Using Compounds Activated by Light by Dunkel, Petra & Ilaš, Janez
cancers
Review
Targeted Cancer Therapy Using Compounds Activated by Light
Petra Dunkel 1 and Janez Ilaš 2,*


Citation: Dunkel, P.; Ilaš, J. Targeted
Cancer Therapy Using Compounds
Activated by Light. Cancers 2021, 13,
3237. https://doi.org/10.3390/
cancers13133237
Academic Editors: Neha Kaushik and
Petra Wilder-Smith
Received: 23 April 2021
Accepted: 24 June 2021
Published: 29 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Organic Chemistry, Semmelweis University, 1092 Budapest, Hungary;
dunkel.petra@pharma.semmelweis-univ.hu
2 Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia
* Correspondence: janez.ilas@ffa.uni-lj.si; Tel.: +386-1-4769-576
Simple Summary: Cancer is among the leading causes of death, and cancer therapy suffers from
many drawbacks, the lack of selectivity being most noteworthy. In this review, we present innovative
approaches in the discovery of novel anticancer compounds, which can use light activation to achieve
more potent cancer therapy with fewer side effects. We describe recent approaches to prepare
photocages and photoswitches and obstacles that photopharmacology must overcome to achieve
clinical use.
Abstract: Cancer chemotherapy is affected by a modest selectivity and toxic side effects of phar-
macological interventions. Among novel approaches to overcome this limitation and to bring to
therapy more potent and selective agents is the use of light for selective activation of anticancer
compounds. In this review, we focus on the anticancer applications of two light-activated approaches
still in the experimental phase: photoremovable protecting groups (“photocages”) and photoswitches.
We describe the structural considerations behind the development of novel compounds and the
plethora of assays used to confirm whether the photochemical and pharmacological properties are
meeting the stringent criteria for an efficient in vivo light-dependent activation. Despite its immense
potential, light activation brings many challenges, and the complexity of the task is very demanding.
Currently, we are still deeply in the phase of pharmacological tools, but the vivid research and rapid
development bring the light of hope for potential clinical use.
Keywords: photocages; photoswitches; photopharmacology; light-activatable materials; photore-
sponsive drug delivery systems; azobenzenes
1. Introduction
Cancer chemotherapy is affected by a modest selectivity and toxic side effects of
pharmacological interventions [1]. Therefore, besides finding novel, efficient, targeted
antitumor agents, developing innovative solutions for endowing cancer chemotherapeutics
with a more selective, localized effect is of paramount importance. Applying various
internal (e.g., pH, redox environment, enzymatic processes) or external triggers (e.g.,
ultrasound, magnetic field, light irradiation) for on-site activation of stimuli-sensitive
drug molecules or drug delivery systems (as, e.g., liposomes, micelles, polymeric or metal
nanoparticles, dendrimers) [2–4] has long been in the forefront of research interest. Of the
potential physical stimuli, light is particular from several aspects, from its orthogonality
with biological systems to the precise control over the wavelength and the irradiation
dose. Light activation is independent of the properties of the tumor environment as well,
allowing to target a variety of tumors. Light-activated approaches made their way into
clinical use already in the 1990s, with the approval of the first photodynamic therapy
regimes [5]. Photodynamic therapy (PDT) is based on the interaction of photosensitizer
agents with light to produce singlet oxygen and superoxide in the presence of molecular
oxygen and the local cytotoxic effect of these species. The discussion of PDT is beyond the
scope of the present review, that will focus on the anticancer applications of two further
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light-activated approaches still in the experimental phase: photoremovable protecting
groups (“photocages”) and photoswitches (illustrated in Figure 1 by the examples of a
photocaged vs. a photoswitchable agent). The concept of photopharmacology was recently
introduced to describe the area dealing with photocontrollable molecules for therapy.
In this review, we focus on small-molecule approaches, where a parent drug itself is
rendered photoactivatable via structural modifications, and the approach is backed up by
in cellulo assays. However, more complex drug delivery systems could also be rendered
light-responsive by judiciously designing photoactivatable units into their structure [6,7].
For such approaches and designs where photoactivation is used for controlling targeting
or cell penetration [8,9] (i.e., not directly the drug activity), we refer to the respective
reports and reviews (e.g., (upconversion) nanoparticles [10–15], organic nanoparticles [16],
chitosan nanoparticles [17], gold nanoparticles [18], photocaged folate nanoconjugates [19],
two-photon nanoimpellers [20], photoresponsive antibody-drug conjugates [21,22]).
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2. Irreversible Activation with Light: Photoremovable Protecting Groups (“Photo-
cages”) for Antitumor Applications 
The first application of photoremovable protecting groups (PPGs) as experimental 
tools for biological studies dates back to the 1970s. The photocage terminology coined at 
the advent of the field might be now ambiguous; therefore, nowadays, the photoremova-
ble/photolabile/photoactivatable protecting group is commonly used in the literature. The 
design rationale behind PPGs is to mask the biological activity of a given substrate by 
covalently binding the protecting group to a moiety critical for the action (“caging”). The 
activity can be restored on demand in a spatiotemporally controlled manner by removing 
the PPG with light irradiation, i.e., the absorbed energy is translated into a photocleavage 
reaction (“uncaging”) [23]. The activation is irreversible, which is often considered as a 
disadvantage of the approach, as the released agents might still lead to unwanted effects 
upon diffusion or excretion. On the other hand, several PPG families of different proper-
ties are available, and temporary deactivation of the parent drug by adding a PPG is typ-
ically more straightforward due to the often significant structural differences upon caging. 
Moreover, with appropriate designs, dual or sequential, the wavelength-selective release 
of different agents could be envisaged as well (“chromatic orthogonality”) [24–28]. The 
PPGs used in the discussed studies with the respective uncaging wavelengths are sum-
marized in Figure 2. 
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(“Photocages”) for Antitumor Applications
The first application of photoremovable protecting groups (PPGs) as experimental
tools for biological studies dates back to the 1970s. The photocage terminology coined at
the advent of the field might be now ambiguous; therefore, nowadays, the photoremov-
able/photolabile/photoactivatable protecting group is commonly used in the literature.
The design rationale behind PPGs is to mask the biological activity of a given substrate by
covalently binding the protecting group to a moiety critical for the action (“caging”). The
activity can be restored on demand in a spatiotemporally controlled manner by removing
the PPG with light irradiation, i.e., the absorbed energy is translated into a photocleavage
reaction (“uncaging”) [23]. The activation is irreversible, which is often considered as a
disadvantage of the approach, as the released agents might still lead to unwanted effects
upon diffusion or excretion. On the other hand, several PPG families of different properties
are available, and temporary deactivation of the parent drug by adding a PPG is typically
more straightforward due to the often significant structural differences upon caging. More-
over, with appropriate designs, dual or sequential, the wavelength-selective release of
different agents could be envisaged as well (“chromatic orthogonality”) [24–28]. The PPGs
used in the discussed studies with the respective uncaging wavelengths are summarized
in Fig re 2.
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in vitro applications, such as proper solubility, stability of the molecule to be released by 
light irradiation, efficient masking of the activity, clean and rapid photorelease, and cel-
lular tolerance to the products of the photoreaction and the applied irradiation (dose-in-
tensity, wavelength). The typical workflow for the rational design and evaluation of pho-
toactivatable antitumor agents consists of the following steps: (i) determining the key 
pharmacophore for introducing the PPG unit, so that either the key ligand-target interac-
tions are disturbed, or spatial conflicts arise rendering the caged drug inactive, (ii) as-
sessing the photostability of the parent drug, so that its activity remains intact upon the 
light irradiation used for the uncaging step, (iii) assessing the hydrolytic stability of the 
caged prodrug at physiological pH, so that the parent drug is released exclusively upon 
light irradiation, (iv) determining the pharmacological activity of the parent and the caged 
drug molecule, assessment of the efficiency of masking (e.g., target enzyme inhibition, 
cellular assay), (v) studying the photolysis of the caged molecule, determining the condi-
tions necessary for uncaging (wavelength and intensity of light irradiation, irradiation 
time necessary for complete conversion), (vi) determining the pharmacological activity of 
the caged molecule in the absence of light and following light irradiation, assessment of 
the efficiency of restoring the pharmacological activity, and (vii) verifying the tolerance of 
the experimental system to the light irradiation applied. Novel probes are typically char-
acterized by UV/VIS absorption, hydrolytic stability, photocleavage rates, and quantum 
yields. Despite the complexity of the task [32], there is rapid development, and novel re-
sults on caged anticancer agents are discussed in the following sections. 
2.1. Kinase Inhibitors 
Kinase inhibitors affecting cell signaling pathways implicated in oncogenesis offer 
targeted therapy against specific malignant diseases. Introduced into therapy in the 2000s 
(2001—imatinib), the number of approved small-molecule kinase inhibitors was steadily 
growing. Although kinase inhibitors are the flagship of targeted therapy, their application 
is not without its challenges (e.g., development of resistance); therefore, they are a prime 
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a ic rocesses, artic larl i t e fiel of neurophysiology [29,30]. oreo er, t e
nu ber of studies on PPG-based light-activatable prodrug designs is steadily growing [31].
An optimal PPG-substrate construct should comply with several criteria already for in vitro
applications, such as proper solubility, stability of the molecule to be released by light irradi-
ation, efficient masking of the activity, clean and rapid photorelease, and cellular tolerance
to the products of the photoreaction and the applied irradiation (dose-intensity, wave-
length). The typical workflow for the rational design and evaluation of photoactivatable
antitumor agents consists of the following steps: (i) determining the key pharmacophore
for introducing the PPG unit, so that either the key ligand-target interactions are disturbed,
or spatial conflicts arise rendering the caged drug inactive, (ii) assessing the photostability
of the parent drug, so that its activity remains intact upon the light irradiation used for the
uncaging step, (iii) assessing the hydrolytic stability of the caged prodrug at physiological
pH, so that the parent drug is released exclusively upon light irradiation, (iv) determin-
ing the pharmacological activity of the parent and the caged drug molecule, assessment
of the efficiency of masking (e.g., target enzyme inhibition, cellular assay), (v) studying
the photolysis of the caged molecule, determining the conditions necessary for uncaging
(wavelength and intensity of light irradiation, irradiation time necessary for complete
conversion), (vi) determining the pharmacological activity of the caged molecule in the
absence of light and following light irradiation, assessment of the efficiency of restoring the
pharmacological activity, and (vii) verifying the tolerance of the experimental system to the
light irradiation applied. Novel probes are typically characterized by UV/VIS absorption,
hydrolytic stability, photocleavage rates, and quantum yields. Despite the complexity of
the task [32], there is rapid development, and novel results on caged anticancer agents are
discussed in the following sections.
2.1. Kinase Inhibitors
Kinase inhibitors affecting cell signaling pathways implicated in oncogenesis offer
targeted therapy against specific maligna t diseases. Introduce i to therapy in the
2000s (2001—imatinib), the number of pproved small-molecule kinase inhibitors was
steadily growing. Although kin se inhibitors are th flagship of targeted therapy, their
application is not without its challenges (e.g., development of resist nce); therefore, they
are a prime choice for further developments. The design of photoactivatable protein kinas
inhibitors has been ext nsively studied by Peifer and coworkers (Figure 3). They designed a
photoactivatable prodrug for imatinib [33], the Bcr-Abl tyrosine kinase inhibitor, which was
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approved for treating Philadelphia chromosome-positive chronic myelogenous leukemia,
but started to be also used for other malignancies. Docking studies of imatinib in the ATP
binding pocket of PDGF-Rβ showed two potential positions for attaching a PPG group to
mask bioactivity: the NH in the benzanilide and in the N-arylpyrimidine-2-amine moieties,
of which the first design was pursued in the study. As PPG, two groups were tested: a
4,5-dimethoxy-2-nitrobenzyl (DMNB) (1) and a coumarylmethyl scaffold (2); however, only
the former provided efficient photorelease of imatinib in vitro at 365 nm (1 mM DMSO
solution, 5.4 W, 10 min). In an enzymatic PDGF-Rβ assay, a 100-fold difference was detected
between the parent imatinib (IC50 = 0.059 µM) and its caged prodrug (IC50 = 5.8 µM). The
residual activity was assumed to originate from uncaged imatinib contaminating the sample.
Following 365 nm irradiation, the bioactivity of imatinib could be nearly totally restored
in vitro in the PDGF-Rβ assay, experimentally confirming a successful caging approach,
while further bioactivity studies were not reported.




Figure 3. Photocaged kinase inhibitors, the PPG indicated in blue. 
The same group also reported photoactivatable caged prodrugs for 3,4-diarylmalei-
mide antiangiogenic VEGFR-2 kinase inhibitors [35,36]. Based on the analysis of key lig-
and-target interactions by molecular docking, the hinge binder region was masked by a 
PPG unit (DMNB), potentially rendering the molecules inactive also toward other protein 
kinases. Docking of the caged prodrugs verified that protection disrupts key H-bond in-
teractions to the hinge region as well as leads to steric hindrance hampering the access to 
the binding pocket. Uncaging was studied with 365 nm irradiation, confirming efficient 
photolysis of 7 (365 nm LED reactor, 5.4 W, 1 mM solution in DMSO, >90% conversion in 
5 min) while the irradiation of compound 6 leads to a 1,6-π-electrocyclization not followed 
by oxidation to carbazole, making this derivative a less suitable candidate for further stud-
ies. VEGFR-2 kinase inhibitory assays confirmed a significant difference (300-fold) in the 
activity of the caged and the parent compounds. The same tendency was also observed in 
the in vitro antiproliferative assays (VEGFR-2 dependent PC-3 cells); however, in both 
studies, the caged inhibitors still showed some activity, ascribed to the presence of resid-
ual non-caged parent compound (GI50: 6—not reached (parent drug—6.4 µM); 7–35 µM 
(parent drug—0.2 µM)). Dose-response curves were recorded for both the parent and the 
caged compounds before and after irradiation (365 nm, 110 mW/cm2, 5 min). The activity 
of the parent drug was restored for compound 7, whereas interestingly an increased ac-
tivity was observed for compound 6 (GI50 after irradiation: 6—0.1 µM (parent drug—2.9 
µM); 7—0.2 µM (parent drug—0.4 µM)). This was presumed to result from several factors: 
restored activity of the kinase inhibitor, the activity of the cyclized intermediate formed 
upon irradiation, the antiproliferative effect of the cleaved cage itself (confirmed by con-
trol experiments with Boc-Ala and DMNB-Boc-Ala model compounds, DMNB-Boc-Ala: 
GI50 = 50 µM) and a synergistic effect of the UV irradiation. Although tolerable in the stud-
ied case, the pharmacological effect or toxicity of the PPG itself might be a serious concern 
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Vemurafenib (a BRAFV600E serine/threonine kinase inhibitor) was approved for late-
stage melanoma in 2011. Besides its therapeutic importance, vemurafenib tolerates the
365 nm UV irradiation relatively well, and chemical modifications could be straightfor-
wardly carried out on its structure; therefore, it is an ideal candidate for the photoactivatable
prodrug approach [34]. Photocaging would allow reaching higher target concentrations
and thus avoid typical side effects, a high incidence of arthralgia (joint pain), skin rash,
and the development of squamous cell carcinoma, which appear with higher dosage. Key
pharmacophoric moieties for efficiently masking the activity of vemurafenib were deter-
mined by docking studies. In the subsequent work, tw potential NH protection sites
were assessed using o-nitrobenzylic PPGs (DMNB and 4,5-dime h x -2-ni r phenylethyl
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(DMNPE)), protection on the azaindole (3,4), and protection on the sulfonamide moiety (5)
of vemurafenib. The former was expected to diminish hinge binding and therefore diminish
activity on other kinases as well, whereas the latter was expected to allow residual activity
on further kinases. As N-heterocycles are rarely described leaving groups, the authors
studied the minimal structural requirements for the photoreaction as well, irradiating
caged fragments of the parent compound besides the fully armed prodrugs (365 nm LED
reactor, 5.4 W, 10 µM solutions in PBS buffer containing 10% DMSO, >90% conversion
in 1 min). Regarding the photoreaction (i.e., rapid and quantitative photorelease), both
protection sites proved to be feasible.
Next, the BRAFV600E binding activity of vemurafenib and its caged prodrugs was
determined, confirming a lower binding affinity for the caged inhibitors (Kd: vemurafenib—
10 nM, 3—440 nM, 4—77 nM, 5—79 nM, overall ~8–40-fold difference). The selectivity
profile was determined on a panel of 140 kinases, and in line with the modeling results,
the azaindole-protected derivative 3 proved to be the most selective (activity on 2 kinases,
vs. 13 for the sulfonamide-protected derivative 5 and 32 for vemurafenib). Antiprolifer-
ative activities were assessed in cellular growth assays (SKMel13, SKMel28, M14, and
UACC62 melanoma cell lines), the caged compounds showing cytostatic activity at higher
concentrations vs. the nanomolar cytotoxicity of the parent vemurafenib (GI50(SKMel13):
vemurafenib—0.17 µM, 3—no cell growth inhibition, 4—4.3 µM, 5—2.6 µM,). Irradiating
the cells (SKMel13, 1.8 W, 5 min) at 365 nm after compound incubation, the cytotoxic activ-
ity of vemurafenib could be restored, although not totally, presumably due to incomplete
photorelease (GI50: vemurafenib—0.19 µM, 3—1.5 µM, 4—0.46 µM, 5—0.35 µM). In control
experiments using Boc-Ala and Boc-Ala-DMNB model compounds, also the cleaved PPG
itself was found to have antiproliferative activity, however at much higher concentrations
than vemurafenib (GI50 = 34 µM). As further proof of restoring vemurafenib activity, the effect
of caged molecules on ERK phosphorylation (SKMel13 cells) following UV irradiation was
studied by Western blot analysis (complete suppression of ERK phosphorylation above
0.1 µM concentrations, dose dependency correlating with that of vemurafenib).
The same group also reported photoactivatable caged prodrugs for 3,4-diarylmaleimide
antiangiogenic VEGFR-2 kinase inhibitors [35,36]. Based on the analysis of key ligand-
target interactions by molecular docking, the hinge binder region was masked by a PPG
unit (DMNB), potentially rendering the molecules inactive also toward other protein
kinases. Docking of the caged prodrugs verified that protection disrupts key H-bond
interactions to the hinge region as well as leads to steric hindrance hampering the access to
the binding pocket. Uncaging was studied with 365 nm irradiation, confirming efficient
photolysis of 7 (365 nm LED reactor, 5.4 W, 1 mM solution in DMSO, >90% conversion in
5 min) while the irradiation of compound 6 leads to a 1,6-π-electrocyclization not followed
by oxidation to carbazole, making this derivative a less suitable candidate for further
studies. VEGFR-2 kinase inhibitory assays confirmed a significant difference (300-fold)
in the activity of the caged and the parent compounds. The same tendency was also
observed in the in vitro antiproliferative assays (VEGFR-2 dependent PC-3 cells); however,
in both studies, the caged inhibitors still showed some activity, ascribed to the presence
of residual non-caged parent compound (GI50: 6—not reached (parent drug—6.4 µM);
7—35 µM (parent drug—0.2 µM)). Dose-response curves were recorded for both the parent
and the caged compounds before and after irradiation (365 nm, 110 mW/cm2, 5 min).
The activity of the parent drug was restored for compound 7, whereas interestingly an
increased activity was observed for compound 6 (GI50 after irradiation: 6—0.1 µM (parent
drug—2.9 µM); 7—0.2 µM (parent drug—0.4 µM)). This was presumed to result from sev-
eral factors: restored activity of the kinase inhibitor, the activity of the cyclized intermediate
formed upon irradiation, the antiproliferative effect of the cleaved cage itself (confirmed by
control experiments with Boc-Ala and DMNB-Boc-Ala model compounds, DMNB-Boc-Ala:
GI50 = 50 µM) and a synergistic effect of the UV irradiation. Although tolerable in the
studied case, the pharmacological effect or toxicity of the PPG itself might be a serious
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concern in therapeutic applications. On the positive side, caging did not hamper the
cellular uptake of the inhibitors (studied on live PC-3 cells by fluorescence microscopy).
While looking at the photocaged kinase inhibitors, it is also worth noticing that several
kinase inhibitors intrinsically possess interesting photochemical properties. Phototoxic-
ity was reported for vemurafenib [37], while dabrafenib can be photodegraded to a novel
fluorescent BRAFV600E inhibitor [38].
2.2. Anthracyclines
Anthracyclines have broad use in cancer chemotherapy, with a wide activity spectrum
(e.g., solid tumors, hematological malignancies, soft tissue sarcomas). Regarding their
activity, intercalation with DNA, affecting DNA replication and transcription and interac-
tion with topoisomerase II have been studied. However, a very effective anticancer agent,
the therapeutic use of doxorubicin is limited notably by its cardiotoxicity. For constructing
a photoactivatable prodrug, Esener and coworkers bound a PPG unit (an o-nitrophenyl
group) to an active amine on the sugar moiety of doxorubicin, a modification already demon-
strated to decrease its toxicity [39]. Additionally, the construct was armed with a biotin
group, linked via a water-soluble glycol spacer, for enhanced membrane interaction (8)
(Figure 4). Biotin was intended to increase the clearance rate of the PPG-drug-construct
and as well PPG fragment from the circulating blood using clearing agents after UV ex-
posure. First, the release and release kinetics of doxorubicin in vitro upon UV irradiation
was measured by LC-MS and NMR studies (in DMSO/water 1/9, 350 nm, 120 or 240 s of
2.19 mW/cm2 irradiation; kinetics: in DMSO/water 2/8, 350 nm, 0 to 10 min, 1.8 mW/cm2
irradiation: 1.8 µM/min doxorubicin release). The uptake and intracellular localization
of the PPG construct vs. free doxorubicin (in 5 vs. 50 µM concentration) was studied in
live PTK2 cells, using the intrinsic red fluorescence of doxorubicin (free or photocaged).
Unlike the parent drug, the PPG construct was not entering the nucleus before light ex-
posure, however following UV irradiation (60 s), the released free doxorubicin behaved
similarly to the parent drug. Cytotoxicity was measured on A549 human lung cancer cells,
showing a significant difference between the parent and the photocaged drug (doxorubicin:
IC50 = 1.2 µM, doxorubicin-PPG construct: IC50 = 250 µM); however, the activity could be
efficiently restored by UV irradiation in a light dose-dependent manner (samples were UV-
irradiated in the media before incubation of the cells, i.e., cells were not irradiated directly.
Maximal effect at 60 min: IC50 = 3.5 µM). To assess the feasibility of future applications, in
a control experiment, A549 cells were irradiated (1.8 mW/cm2) but retained cell viability
after 20 min of irradiation (after 60 min, 90% cell viability was recorded). To ascertain that
drug release occurs only upon UV irradiation, the metabolic stability of the doxorubicin-PPG
construct was verified using human liver microsomes. One major metabolite was identified,
however, in small quantities, and its effect was not studied. Importantly, further in vivo
studies were conducted [40]. First, the penetration of 365 nm light through ex vivo tumor
tissue (irradiation from the center, penetrating light intensity measured at different angles)
and the release of doxorubicin was measured using a LED/fiber-optic system (efficient
release after 30 min irradiation). For conducting in vivo experiments, the doxorubicin-PPG
construct was solubilized using Captisol® cyclodextrin to allow a concentration of 1.2 mg
in 200 µL of saline. The circulation was studied in vivo (female nude mice, alpha phase
circulation half-life 10 min vs. ~20 min for doxorubicin). Of note, no free doxorubicin was
detected neither in the serum nor in the urine out to 24 h, ascertaining UV irradiation as
the major activation mode in subsequent experiments. In vivo drug release was studied on
athymic nu/nu nude mice. A total of 10 min after injecting the doxorubicin-PPG construct
(time point chosen based on the circulation half-life), a 365 nm LED was inserted into the
middle of the tumor and turned on (240 µW/cm2, 30 min irradiation). A control tumor was
left unirradiated, and blood samples were taken to monitor circulating drug concentration,
whereas tumor samples were collected to analyze the distribution of the construct and the
free drug. The construct was found in all tumor tissue sections of both the irradiated and
unirradiated tumors, whereas a trace amount of doxorubicin was found in some sections of
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the unirradiated tumors vs. an increased doxorubicin content at the irradiation site (~6-fold
difference in doxorubicin/gram of tumor tissue between irradiated and unirradiated tu-
mors). The former was ascribed to the effect of UV leakage. No doxorubicin was detected in
the serum sample taken after irradiation, pointing toward a controllable systemic exposure.
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For therapeutic applications, using appropriate (longer) wavelengths has several 
practical consequences. One approach to harness long wavelengths, consequently low-
energy photons, is to target sufficiently weak chemical bonds that could be directly 
cleaved with lower energy. Lawrence and coworkers aimed to exploit the photohomolysis 
of the C-Co bond (<30 kcal/mol) in alkyl-cob(III)-alamins. The bond is weak enough to be 
cleaved by any wavelengths between 330 and 560 nm absorbed by the corrin ring system 
[46]. To move further toward the optical window of tissues and to develop wavelength-
tunable probes, constructs with additional fluorophores serving as light-capturing anten-
nas were designed (TAMRA, SulfoCy5, Atto725, DyLight800, Alexa700, Bodipy650). The 
design rationale was that upon excitation beyond cobalamin absorption wavelengths, the 
Figure 4. Photocaged doxorubicin derivatives, the PP indicated in blue.
Choi and coworkers studied the design nd synthesis of a novel thioacetal
ortho-nitrobenzald hyde (TNB) dual-arm p otocage [41] and its applicati for co structing
dual drug-fluorescent reporter conjugates for controlled release and real-time fluor scent
monitoring of drug activation in parallel. Optimally the two pay ads are released simul-
taneously by cleaving the linker C-S bonds resist nt to many chemical conditions), and
several combinations of argeting ligands, rugs, etc., might be envisaged. For one set
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of drug-TNB-fluorescent reporter conjugates, doxorubicin was used as model anticancer
substrate (doxorubicin-TNB-coumarin (9) (carbamate linkage)). The cleavage mechanism of
the free cage was studied at 365 nm by 1H NMR, UV/VIS, and UPLC monitoring. A total
of 365 nm photolysis of the cage conjugate in water/MeOH 1/1 led to an efficient release
of the drug and reporter molecules presumably via a self-immolative mechanism (decay
half-life (t1/2) < 2 min, Φuncaging = 0.08), the latter leading to an irradiation-dependent
increase in fluorescence (i.e., the reporter is in a fluorescently quenched state before cleav-
age). The construct showed irradiation-dependent cytotoxicity in FAR(+) KB cells (before
irradiation 9: IC50 = 9.2 µM; after irradiation 9: IC50 = 0.84 vs. doxorubicin: IC50 = 0.04 µM).
Hartman and coworkers studied the photocaging of 2-pyrrolino doxorubicin
(2P-Dox) (10), a derivative of the standard doxorubicin, starting from its known diacetoxy
prodrug [42]. Photorelease upon UV irradiation showed 88% release after 60 min irradia-
tion, which corroborated by MS and HPLC results (20 mM in PBS, 380 nm, 9.0 mW/cm2).
Cellular viability assays (CellTiter-Blue method) were run in three human cancer cell lines:
MCF-7 (breast), A2780 (ovarian), and A2780ADR (doxorubicin-resistant ovarian), demon-
strating a significant increase (327–750-fold) in activity upon light irradiation (380 nm,
30 min), activities compared with the parent drug. As a negative control, the released PPG
itself was not cytotoxic up to 50 µM. Cellular uptake in MCF-7 cells was studied by flow
cytometry, exploiting the fluorescence of doxorubicin and compound 10. Compound 10
showed a higher cellular uptake than doxorubicin, in line with previous observations regard-
ing the effect of alkylation with lipophilic moieties. Confocal microscopic studies indicated
a nuclear co-localization of compound 10 and doxorubicin.
Controlled photorelease of the drug molecules could be combined with cell target-
ing to increase selectivity. Folic acid conjugates are often used to target overexpressed
folate receptors (FRα) on tumor cells [43]. To release the internalized drug and avoid
endosomal entrapment, Hartman and coworkers designed a photoactivatable folic acid-
drug conjugate [44]. The conjugate consisted of folic acid, a PEG linker, and photocaged
doxorubicin (11), using a DMNB unit as PPG (Figure 4). UV photolysis of the conjugate
resulted in rapid release of doxorubicin (HPLC monitoring); however, no further biological
assays were pursued.
Of further targeted carrier approaches beyond small molecules, Choi et al. described
polyamidoamine (PAMAM) dendrimer nanoconjugates with folic acid ligands armed with
a photocaged doxorubicin (using an ortho-nitrobenzyl based PPG). In vitro, on folic-acid-
receptor-over-expressing KB cells, the doxorubicin constructs inhibited cell growth in an
irradiation dose-dependent manner (but not without irradiation). The maximum effect
observed (30 min irradiation, ~80% cell growth reduction) was comparable to the effect of
the parent drug (~85% cell growth inhibition) [45].
For therapeutic applications, using appropriate (longer) wavelengths has several prac-
tical consequences. One approach to harness long wavelengths, consequently low-energy
photons, is to target sufficiently weak chemical bonds that could be directly cleaved with
lower energy. Lawrence and coworkers aimed to exploit the photohomolysis of the C-Co
bond (<30 kcal/mol) in alkyl-cob(III)-alamins. The bond is weak enough to be cleaved by
any wavelengths between 330 and 560 nm absorbed by the corrin ring system [46]. To move
further toward the optical window of tissues and to develop wavelength-tunable probes,
constructs with additional fluorophores serving as light-capturing antennas were designed
(TAMRA, SulfoCy5, Atto725, DyLight800, Alexa700, Bodipy650). The design rationale
was that upon excitation beyond cobalamin absorption wavelengths, the antennas might
transfer excited-state energy to the corrin ring (coenzyme B12), thus contributing to Co-C
bond cleavage. The full conversion was observed upon irradiation at the corresponding
wavelength (Xe flash-lamp, 546 nm, 25 min); moreover, the constructs released the fluo-
rophores also at the longer wavelengths (646/730/780 nm). Photorelease could also be
operated by linking the fluorophores to the ribose 5′-OH of alkylcobalamins. To assess
the application of cobalamin conjugates as drug delivery systems, a cobalamin-doxorubicin
conjugate was prepared (12) [47]. Cytotoxicity was studied in HeLa (cervical cancer) cells
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(MTT assay at 10 µM), following different illumination times (30, 45, and 75 s at 530 nm).
The cobalamin-conjugate affected cell viability in an irradiation-dependent manner (neither
the construct without light nor the light irradiation without the construct had an effect on
cell viability), with similar efficacy at the end point as that of the parent doxorubicin.
Hartman and coworkers also envisaged modulating the cellular entry of a cytotoxic
agent by a photocage approach (photocaged permeability), linking doxorubicin as the
model drug to a polar sulfonic acid fluorophore (EDANS) via a photocleavable nitro-
veratryl PPG (13) [48]. Photolysis was evaluated in PBS by HPLC monitoring (365 nm,
9.0 mW/cm2), showing parent drug release. The effect on cellular entry was studied on
JH-EsoAd1 cells (Barrett’s esophagus associated adenocarcinoma cell line) under dark
and light-irradiated conditions with flow cytometry. An irradiation-dependent fluores-
cence enhancement was observed both with flow cytometry and confocal microscopic
studies. Cell viability was assessed with MTT assay, showing a clear correlation between
decreased survival and light irradiation (365 nm, 9.0 mW/cm2, 20 min) of the probes (Dox:
IC50 = 1.0 µM, EDANS-DOX: no toxicity till 16 µM, EDANS-DOX-lit: IC50 = 1.6 µM).
2.3. Tubulin (Dis)Assembly Inhibitors, Microtubule-Targeting Agents
Paclitaxel (PTX) has a broad antitumor activity spectrum (e.g., breast, ovarian, head
and neck cancers, malignancies resistant to conventional chemotherapy). Its action is based
on affecting tubulin polymerization and microtubule dynamics, thereby disrupting cell
division and interphase mechanisms and leading to cell death. Given the widespread
therapeutic applications of PTX and the challenges limiting its use (e.g., resistance mecha-
nisms, neuro-, and hematological toxicities), it is not surprising that several research groups
proposed different photoactivatable prodrug designs. As one of the first examples, Kiso
and coworkers linked a 7-N,N-diethylamino-4-hydroxymethyl coumarin (DECM) PPG to
the O-acyl isoform of the parent drug (14) (Figure 5) [49]. Previous SAR studies suggested
that the introduction will render the drug inactive (i.e., the structural modification is carried
out at a key pharmacophore). Due to solubility reasons, the photolysis was studied in a
1/1 mixture of PBS and methanol at 430 nm (diode laser, 10 mW), monitored by UV/VIS
absorption and HPLC (recovery rate: 69% after 30 min irradiation). The photorelease prod-
uct subsequently yields the parent paclitaxel through O-N acyl migration at a reasonable
rate under physiological conditions. To solve the solubility issue, a new coumarin PPG
with improved water solubility was designed in a follow-up study by the same group [50]
and linked to paclitaxel as carbonate (15), and 3′-N-debenzoylpaclitaxel (as carbamate, 16)
respectively (solubility over 100 mg/mL vs. 0.00025 mg/mL for paclitaxel). Despite the
suitable water solubility, the carbonate prodrug was not stable enough under physiological
conditions; therefore, it was not studied further (20% paclitaxel release after 8 h incubation
at pH 7.4, 37 ◦C). In vitro photorelease from the carbamate, prodrug was studied in PBS,
depending on the light source providing 24% (355 nm pulse laser, 10 Hz, 5 mJ, 4 min) or
69% (365 nm 6W UV-lamp) recovery rate of the parent paclitaxel. The lower recovery rate
in the former case was ascribed to the sensitivity of the protecting group to intense light
irradiation, besides the wavelength. No further biological assays were pursued, however.
Del Campo and coworkers used a 4,5-dimethoxy-2-nitrobenzyloxycarbonyl (Nvoc)
PPG for preparing photocaged paclitaxels by blocking either one or both of two reactive
hydroxyls (C2’, C7) critical for bioactivity (17, 18, 19) [51]. Photolysis of the caged probes
was studied in ACN (5% water, 1 mM) solutions, with UV and HPLC monitoring (360 nm,
2.7 mW/cm2, chemical yields of PTX release: 17—61%, 18—89%, 19—52%). In in vitro
microtubule polymerization assay under dark and lit conditions, 7-Nvoc-PTX (18) showed
residual activity, whereas 2′-Nvoc-PTX (19) and 2′,7-bisNvoc-PTX (17) operated only after
UV exposure. However, for the double-protected drug, higher doses were necessary
to obtain the same amount of released drug (according to HPLC studies, a sequential
deprotection occurs). In cellular assay on HeLa cells, both monoprotected probes showed
cytotoxicity, normal cell morphology was detected only following 2′,7-bisNvoc-PTX (17)
treatment. Treatment with pre-irradiated probes led to similar results as observed with free
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PTX (i.e., the activity could be restored). Assessing cell viability in liquid HeLa cell culture,
2′,7-bisNvoc-PTX (17) was not cytotoxic till 10 µM, whereas 2′-(19) and 7-Nvoc-PTX (18)
showed ~50% viability at 0.1 µM. A further demonstration of the need for double protection.
Masking of activity and restoring it upon pre-irradiation was also confirmed in in vitro
assays of microtubule catastrophes and mitotic index (HeLa cells). In situ photolysis by
a short light pulse under a fluorescent microscope resulted as well in the reorganization
of microtubules.
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To broaden the structural diversity of PPGs, Furuta and coworkers designed a mod-
ular 6-bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) group that has a terminal alkyne moi-
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o broaden the structural diversity of P Gs, Furuta nd coworkers designed a modular
6-bromo-7-hydroxyc umarin-4-ylmethyl (Bhc) group that has terminal alkyne moiety
allowing furthe functionalization via click chemistry and used it for he synthesis of caged
PTXs [52]. Besides a Bhc cage-PTX conjugate (20, 21), two further probes were prepared
exploiting the alkyne chemical handle (22), one functionalized with a sugar to improve
water solubility (23), and another with a halo tag ligand for cellular targeting (24). PTX was
released from all novel probes under in vitro conditions at 350 nm (KMOPS containing 0.1%
DMSO, 10 mJ/s lamp, Φdis = 3.5–14), the improved water solubility of compound 23 also
translating to more efficient photolysis, presumably by promoting ion-pair intermediates
implicated in the reaction. Masking and UV-triggered restoring of the activity of the parent
drug was assessed in an in vitro tubulin polymerization assay (porcine brain tubulin,
turbidity assay at 340 nm), confirming an irradiation-dependent effect (350 nm, 10 mJ/cm2,
60 s) and comparable maximum activity of activated caged compounds with paclitaxel;
however, no animal studies were undertaken.
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For the thioacetal ortho-nitrobenzaldehyde dual-arm photocages described in the previ-
ous section, PTX was used as another study drug (paclitaxel-TNB-fluorescein
(25, ester linkage), paclitaxel-TNB-coumarin (26, ester linkage)). Efficient photorelease
was also detected for the PTX-constructs (25/26: Φuncaging = 0.05/0.07). Cellular uptake
and reactivation after uptake of 25 were studied by fluorescence with flow cytometry in
FAR(+) KB cells. The results confirmed an intracellular accumulation of the PTX-TNB-
fluorescein conjugate 25 and an efficient 365 nm photorelease of the fluorescent reporter
intracellularly (365 nm, 2 min). The correlation between the cytotoxicity and fluores-
cence was studied in a microplate assay on FAR(+) KB cells (XTT assay). Dose-dependent
cytotoxicity was recorded both for irradiated and non-irradiated conjugates; however, cyto-
toxicity prior irradiation was modest compared to the parent drug (before irradiation 25/26:
IC50 = 0.24/0.23 µM; after irradiation 25/26: IC50 = 0.04/0.05 vs. PTX: IC50 = 0.02 µM).
Moreover, the cytotoxicity was in correlation with the increase in fluorescence upon irradi-
ation, paving the way toward quantification and effective real-time monitoring of the drug
release process. Real-time fluorescence in cellular systems was recorded over extended
periods of time following irradiation to study the release kinetics (24 h monitoring, 0.5 or
2 min irradiation). The gradual, continuous increase in fluorescence was ascribed to the
conversion of transient dye intermediates to parent fluorescent probes. On the other hand,
a certain degree of increase in fluorescence was observed for the conjugates even without
UV irradiation after extended periods, i.e., a dark release was occurring.
Dobber et al. designed a photocaged small-molecule tubulin inhibitor starting from
the previously described inhibitor CMPD1 and using DMNB as PPG [53], linked to a
phenolic OH group, the crucial role of which has been confirmed by previous SAR stud-
ies. First, the UV-stability of the parent inhibitor was ascertained at 365 nm, followed
by measuring the kinetics of the photorelease from the cage monitored by HPLC (2.7 W,
τ = 0.61 min, maximum parent drug concentration reached after 2 min irradiation). For as-
sessing the pharmacological effects, cell viability assays on U251 and patient-derived
RN1 glioblastoma cells were used, after first checking their UV-irradiation tolerance
(1.8 mW till 5 min, maximum tolerated light exposure: U251—1 min, RN1—30 s). A
55- and 125-fold difference was recorded between the activity of the parent and the caged
drug without UV irradiation. UV irradiation of the cage-treated cells could recover al-
most totally the cytotoxicity (photocaged drug after irradiation—EC50(U251) = 2.1 µM,
EC50(RN1) = 1.2 µM). Additionally, in control experiments blocking the pharmacophoric
OH with a bulky aromatic group and cytotoxicity of the released DMNB were addressed
(released DMNB did not change cell viability till 100 µM concentration in U251 cells). Loss
of activity of the caged drug and recovering the activity upon UV irradiation were further
addressed in in vitro tubulin polymerization (porcine brain tubulin) and tubulin binding
assays (competitive colchicine binding assay), as well as via assessing the effect on the
tubulin network and cell morphology in U251 glioblastoma cells (immunofluorescence
staining of β-tubulin) and measuring the apoptotic effect on RN1 glioblastoma cells (An-
nexin V staining). All the pharmacological studies pointed toward the release of a bioactive
molecule from the photocage upon UV exposure and inactivity without UV irradiation.
2.4. DNA Alkylating Agents
Alkylating agents cause direct DNA damage (consequent fragmentation, crosslinking
or mutations due to mispairing) and thereby disrupt DNA replication and cell division.
The nitrogen mustards were among the first anticancer chemotherapeutics, and alkylating
agents have widespread use against a variety of hematological and solid tumors. Nitrogen
mustards typically have a bis(2-chloroethyl) group important for action, e.g., also in chlo-
rambucil. Schuberth et al. developed photoactivatable prodrugs for the highly cytotoxic
duocarmycin [54]. Despite their cytotoxic potential (activity in multidrug-resistant cells),
no duocarmycins are yet approved for therapy. (+)-Duocarmycin SA contains a DNA
recognition and a DNA alkylating unit, the latter implicated in forming DNA adducts. In
the cited study, a seco- and a dimeric duocarmycin analog was used as the parent drug, and
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the PPG (3,4-methylenedioxy-ONB—with an additional tert-butyl ester or carboxylic acid
at α-position, overall 5 novel probes) was linked to a phenolic OH to hinder the formation
of the spiro-cyclopropyl unit critical for action (Figure 6). Photorelease was studied in PBS
buffer (1/10% DMSO, 365 nm, 1.1 mW/cm2) with LC-MS monitoring. For compounds 27,
28, the photoreactions proceeded via the expected pathway, i.e., PPG cleavage and subse-
quent cyclization (28: Φ = 0.45). For the 29–31 series, however, the photorelease was slow
and led to the formation of several side products. Cellular cytotoxicity was assessed on
A549 bronchial carcinoma cells (HTCFA-derived test) with pre-irradiated samples (365 nm,
1.1 mW/cm2, 30 min) or without UV exposure. For 27, a more than 106-fold difference of
activity was recorded vs. the parent drug, and the activity could be efficiently restored with
UV exposure. Interestingly, for 28, the PPG construct itself was found to have enhanced
cytotoxicity vs. the free drug. No proper phototherapeutic index values were found for the
29–31 series.
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Several photoactivatable prodrug approaches were described for the aromatic nitro-
gen mustard chlorambucil (Figure 7), used for chronic lymphocytic leukemia, Hodgkin 
lymphoma, and non-Hodgkin lymphoma. Push-pull stilbenes were devised with the aim 
to develop visible light-activated PPGs with turn-on fluorescent real-time monitoring abil-
ity [55]. The PPG was based on a trans-4-(N,N-dimethylamino)-4′-nitrostilbene unit, plac-
ing the substrate (an alcohol or a carboxylic acid) to be liberated at the point of photocy-
clization, serving as a leaving group upon the process. By formation of the cyclized phe-
nanthrene product, a blue fluorescence appears that was used for monitoring of the pho-
torelease. Besides simple model substrates, as model drug molecules for photorelease 
studies, chlorambucil was selected (32). Due to the presence of appropriately placed elec-
tron-donor and –acceptor groups and consequent charge transfer, the novel caged deriv-
atives had an absorption maximum typically above 400 nm, whereas the fluorescence be-
came quenched in polar solvents. The uncaging was studied in ACN (medium-pressure 
mercury lamp (125 W)), with NMR, UV/VIS, HPLC, and MS monitoring with ≥410 nm 
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l , and non-Hodgkin lymphoma. Push-pull stilbenes wer devised with the
aim to develop visible light- ctivated PPGs with turn-on fluoresc nt real-time monitoring
ability [55]. The PPG was based on a trans-4-(N,N-dimethylamino)-4′-nitrostilbene unit,
placing the substrate (an alcohol or a carboxylic acid) to e liberated at the point of pho-
tocyclization, serving as a leaving group upon the process. By formation of the cyclized
phenanthrene product, a blue fluorescence appears that was used for monitoring of the
photorelease. Besides simple model substrates, as model drug molecules for photorelease
studies, chlorambucil was selected (32). Due to the presence of appropriately placed electron-
donor and –acceptor groups and consequent charge transfer, the novel caged derivatives
had an absorption maximum typically above 400 nm, whereas the fluorescence became
quenched in polar solvents. The uncaging was studied in ACN (medium-pressure mercury
lamp (125 W)), with NMR, UV/VIS, HPLC, and MS monitoring with ≥410 nm irradiation,
confirming an efficient liberation of the caged substrates accompanied by an increase
in fluorescence (450 nm) (chlorambucil: Φp = 0.10). Modeling physiological conditions,
uncaging of chlorambucil was also measured in ACN/HEPES (1/19) mixture (λ ≥ 410 nm,
75% release after 1 h, Φp = 0.02). Real-time monitoring of photorelease was studied in
MCF-7 cells by confocal microscopy after different light exposure periods (λ ≥ 410 nm,
0–30 min). Irradiation-dependent cytotoxicity of caged chlorambucil was assessed on MCF-7
cells (MTT assay), confirming a significant drop of cell viability in the irradiated samples vs.
the unlit ones (dark sample: more than 75% cell viability (100 µM), after 30 min irradiation:
15% viability, IC50 = 230 µM).
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Chlorambucil was linked to a first 7-h droxycoumarin, tha was it elf masked with an
o- itrobenzyl PPG quenching its fluorescence (fluorescent quantum yields: oumarin-
hlorambucil (CC)-Φf = 0.49, ONB-CC-Φf = 0.010). To provide tumor-targeting ability, a
biotin ligand was used as well (33). Photolysis as studied with 1H NMR, HPLC, and
fluorescence monitoring (10 µM, water/ACN 4/1, 125 W, ≥365 m). The fluorescence
(546 nm) increased within 5 min irradiation and reached a maximum in 30 min, con-
firming the turn-on ability of the construct. After 5 min irradiation, CC release (90%)
and nitrosobenzaldehyde formation occurred. The second uncaging (chlorambucil release,
70%) necessitated a longer, 20 min irradiation (ho ever, less than 7% release with diode
laser, 730 nm, 30 mW/cm2). Incubating MDA-MB-231 (breast adenocarcinoma) cells with
ONB-CC and subjecting them to a UV-irradiation regime, a gradually intensifying green
fluorescence appeared, confirming intracellular accumulation and CC release. Cytotoxicity
was studied on the MDA-MB-231 cell line with UV irradiation (30 min, ≥365 nm). At
50 µM concentration, a 50% cell viability was observed (vs. chlorambucil IC50 = 67 µM).
Without light irradiation, no significant effect was detected for the drug-PPG construct.
Higher apoptotic activity observed for the biotin-tagged construct in cell cycle analysis
pointed toward a contribution of accumulation to the increased cytotoxicity.
The same group used PPGs for the design of dual drug delivery systems [57]. As a
photoactivatable and fluorescent unit allowing imaging besides caging, an acetly-carbazole
was used, from which single and dual-arm cages were prepared (34, 35). In the latter case,
either two of the same or two different substrates could be linked as esters. Photorelease
was first studied in ACN/water 7/3 solutions at 365 nm using various acid model sub-
strates, confirming a clean process (i.e., formation of the parent 3-(hydroxyacetyl) 9-ethyl
9H carbazole and the uncaged free acid substrate) and suitable recovery of the free acid
(medium-pressure mercury lamp (125 W), Φp ~0.1). Importantly, dual-arm cages released
two equivalents of the linked carboxylic acids, and a simultaneous release occurred in the
case of dual-arm cages with two different acid substrates. For a proof-of-concept study
of dual drug delivery systems, caffeic acid and chlorambucil were selected as the bioactive
antitumor compounds. Photorelease of the parent drugs was verified in ACN/water 7/3
solution (medium-pressure mercury lamp (125 W), 0.1 mM, 60 min irradiation, caffeic acid:
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91% release, Φp = 0.046; chlorambucil: 94%, Φp = 0.051). The cellular uptake of the dual-arm
drug-PPG conjugate was studied in glial cancer cells (U87MG) by confocal fluorescence
at 10 µM concentration (3 h treatment), confirming an internalization of the conjugate.
The in vitro cytotoxicity of the conjugate without and after irradiation was determined
on normal HaCaT cells, confirming feasible biocompatibility (80% cell viability before
irradiation, 40% cell viability after irradiation at 80 µM concentration). The anticancer
activity of single-arm PPG-caffeic acid, PPG-chlorambucil, and the dual-arm PPG-conjugate
was studied on U87MG cells by MTT assay. A significant difference in cell viability was
recorded between the experiments without and after UV irradiation (more than 70%
cell viability for all constructs at 25 µM concentration, after irradiation: PPG-caffeic acid:
IC50 = 15 µM, PPG-chlorambucil 34: IC50 = 15 µM, PPG-caffeic acid-chlorambucil 35:
IC50 = 9 µM).
Further development led to the modifications of the p-hydroxyphenacyl PPG to render
it fluorescent and activatable above 400 nm [58]. A 2-(2’-hydroxyphenyl)benzothiazole unit
was added, known to have a fast and efficient excited-state intramolecular proton transfer
(ESIPT) effect, contributing to interesting fluorescent properties potentially allowing real-
time monitoring of photorelease processes. The novel PPG system was tested for caging
chlorambucil (36). In vitro photorelease was assessed in ACN/HEPES 1/19 (0.1 mM, 410 nm,
medium-pressure mercury lamp (125W), Φu = 0.46, 90% release after 15 min irradiation).
The ESIPT-assisted photorelease mechanism was further addressed with computational
chemistry, supporting a singlet-state ESIPT followed by intersystem crossing (ISC) and
triplet-state photo-Favorskii rearrangement. The in vitro photoreaction was accompanied
by a fluorescent color change from green (517 nm) to blue (450 nm). In the cellular en-
vironment (MDA-MB-231 cells), after internalization of the PPG-chlorambucil constructs,
the photorelease could be followed by confocal microscopy (≥410 nm, 15 min irradia-
tion). Cytotoxicity of the parent and caged drug was assessed on MDA-MB-231 cells with
MTT assay. Without irradiation, the cell viability remained above 90% for different PPG-
chlorambucil concentrations; however, ≥410 nm irradiation efficiently restored the activity
of the parent drug. To address tissue penetration issues, a p-hydroxyphenacyl-based two-
photon (TP) responsive system for caging chlorambucil [59] was also designed. The novel
PPG system showed ESIPT and aggregation-induced emission (AIE) phenomenon. Upon
in vitro photolysis (ACN/PBS buffer) of the PPG-chlorambucil conjugate (37) (≥365 nm),
a fluorescence color change was observed (550→430 nm blue shift), potentially allow-
ing real-time monitoring of the photorelease (0.1 mM, ACN/PBS 1/9, medium-pressure
mercury lamp (125 W), ≥365 nm, 15 min, Φu = 0.49). Drug release could be effectuated
sequentially as well with an on-off irradiation regime, thus verifying the light-dependency
of the process. Uncaging occurred from the aggregate state, as confirmed with irradiation
of the conjugate in the presence of different water fractions. Two-photon photorelease
was confirmed experimentally at 700 nm (0.1 mM in DMSO/water 1/9, 25% release after
3 h) with an open aperture Z-scan technique with a pulsed laser. In vitro cytotoxicity
studies were conducted in MCF-7 (breast cancer) cells, confirming first the cellular uptake
of the conjugate. Upon 15 min ≥ 365 nm irradiation, the fluorescent color change due
to photorelease could be monitored by confocal microscopy, and a concentration- and
irradiation-dependent cytotoxic effect was recorded using the MTT assay (cell viability
above 95% before irradiation, after irradiation IC50 = 31 µM).
2.5. PARP Inhibitors
Poly (ADP-ribose) polymerase (PARP) inhibitors target DNA damage response, partic-
ularly in cancer cells with high replication stress and genomic instability. The first in class
olaparib was approved in 2014, talazoparib in 2018. Indications include BRCA mutated ovar-
ian and breast cancer, and clinical trials addressing further indications and combination
therapies were launched. Weissleder and coworkers aimed to develop a construct allowing
real-time monitoring of intracellular drug transport using a photocaging concept [60]. As
fluorophore, a BODIPY unit was selected, a 2,6-dinitrobenzyl (DNB) as PPG and as the
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study drug a derivative based on the PARP inhibitor olaparib (38) (Figure 8). PPG-binding
quenched fluorescence that was restored upon 365 nm irradiation (1.6 mW/cm2, ~45 min).
In an in vitro PARP1 activity assay, both the caged and released derivatives had activity
in the nanomolar range (38: IC50 = 32 nM, 38-uncaged: IC50 = 68 nM). Cytotoxicity was
measured on MDA-MB-436 cells, showing higher cytotoxicity for the conjugates than the
parent drug (presumably due to increased cellular retention). Real-time monitoring of
cellular drug efflux at single-cell resolution at steady-state conditions was demonstrated
after photoactivation (405 nm laser).
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Zhou and coworkers studied photocaging of talazoparib, an approved oral nanomolar
PARP inhibitor drug [61]. The key pharmacophore for introducing the PPG unit (the
lactam moiety) was determined by molecular docking so that masking disrupts hydrogen
bonding interactions with the protein besides steric clashes to render the caged inhibitor
inactive (39). As PPG, the o-nitrobenzyl unit was selected, allowing fast and complete
release of talazoparib upon 365 nm irradiation (20 µM in methanol, 4.1 mW/cm2, 5 min).
Recording the dose-response curves of talazoparib and its caged counterpart on PARP-1
enzyme, a 380-fold difference was found (talazoparib: IC50 = 0.005 µM, photocaged drug:
IC50 = 1.9 µM). Further assessment of the pharmacological effects at a cellular level (inhibi-
tion of poly ADP-ribosylation in HeLa cells) also showed a significant, 658-fold difference
between the activity of the free and the caged drug molecules. Cytotoxicity of the par-
ent and caged talazoparib was studied in BRCA1- and BRCA2-defective cell lines (MX-1,
Capan-1: talazoparib: IC50 = 0.015 µM and 0.003 µM; photocaged drug: IC50 = 1.9 µM and
0.86 µM), confirming the former tendencies (i.e., the caged version being significantly less
active). For testing whether the pharmacological activity could be restored, the irradia-
tion times were a trade-off between the photolysis conversion and the UV-tolerance of
the cell lines (MX-1/Capan-1—1/3 min). This could be the reason for not obtaining the
maximal pharmacological effect of the parent compound following UV irradiation (MX-1:
IC50 = 0.58 µM, Capan-1: IC50 = 0.092 µM); however, an increased effect was recorded
compared to the caged molecules (3- and 9-fold difference vs. the non-irradiated group).
On the other hand, the released PPG was not found to have cytotoxic effects in the studied
concentrations (using a Boc-Ala-PPG model); therefore, the observed pharmacological
activity could be fully ascribed to the released talazoparib.
2.6. Histone Deacetylase Inhibitors
Epigenetic modulators are an important and large family of anticancer agents, there-
fore a logical choice of great potential for designing photoactivatable agents. Epigenetic
processes have important regulatory functions, and histone acetylation affects DNA tran-
scription and gene expression. The operation of histone deacetylases (HDAC) dimin-
ishes gene transcription and differentiation, and histone modification is implicated as
well in cancer pathogenesis. The first in class pan-inhibitor (class I and II HDACs in-
hibitor) suberoylanilide hydroxamic acid (vorinostat, SAHA) was approved in 2006 for
cutaneous T cell lymphoma. Nakagawa and coworkers studied photocaging of SAHA [62]
used in clinics (40) (Figure 9). The key pharmacophore moiety of HDAC inhibitors is
a zinc-binding group, a hydroxamate in the case of SAHA. Therefore binding the PPG,
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a (7-diethylaminocoumarin-4-yl)methyl group was planned at this site to block activity.
Photorelease was studied in Tris-DMSO (20%) at 400–430 nm with HPLC monitoring
(66 mW/cm2; photodecomposition Φ = 4.5 × 10−3, SAHA release Φ = 1.5 × 10−3), leading
beside the parent inhibitor and the PPG to the formation of partly unidentified side products
as well. The caged drug showed an irradiation-dependent HDAC inhibition (HDAC-Glo
I/II assay kit), whereas the main photoproducts besides the parent drug (7-diethylamino-
4-hydroxymethylcoumarin, suberanilic acid) were ineffective (at 0.5 µM). Cell growth
inhibition studies were conducted on HCT116 cells, confirming a cage concentration- and
light exposure-dependent effect (1, 3, or 10 min irradiations).
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Gasser and coworkers chose a light-stable ferrocene derivative of SAHA (Fc-SAHA)
as a starting point for their studies and masked it with a DMNB moiety at the hydrox-
amic acid (41) [63]. Photorelease kinetics and profile were studied using a UV reactor
(300–400 nm, centered at 350 nm) with LC-MS monitoring (10 min irradiation, 2.79 J/cm2).
Besides the parent drug released, an amide analog of Fc-SAHA was detected, and further
minor unidentified by-products. In vitro HDAC inhibition was tested under dark and
irradiated conditions (10 min, 2.79 J/cm2—dose selected as a trade-off between conversion
and UV-tolerability), confirming an efficient masking (26- to 333-fold) and light-triggered
release of the activity on HDAC1, HDAC2, and HDAC6. The remaining effect of the caged
drug might be a result of insufficient steric bulk of the applied PPG. No further cellular
assays were performed due to insufficient aqueous solubility of the caged drug.
2.7. Metal Complexes
The use of metal-based drugs in cancer therapy has been limited by the challenges
of distinguishing between therapeutic and toxic doses. Cisplatin was approved in the
1970s and is effective against a plethora of cancers. Its activity is based on crosslinking
DNA purine bases, affecting DNA repair processes, leading thereby to DNA damage and
subsequent cell death. Photoactivation in the context of inorganic chemistry started to ap-
pear in the 1990s. Photoactivated chemotherapeutics (PACT) describe approaches wherein
upon light activation, a structural change and consequently a change in bioactivity occurs.
PACT was extended to several metal complexes. The photoactivation could occur via
different mechanisms, as photoreduction, photosubstitution, or C-C bond cleavage. In the
following sections, illustrative examples based on conventional photocage or photoswitch
motifs are presented. For further information on photoactivatable metal complexes, we
refer to the respective literature [32,64,65]. Mari et al. designed RuII–polypyridyl com-
plexes combining a tumor-targeting (a bombesin—BBN or a nuclear localization signal
sequence—NLS) and a light-activatable functionality (an o-nitrobenzyl PPG) to achieve
double selectivity [66]. Three complexes with different ligands conjugated to the PPG
and NLS and three conjugated to the PPG and BBN and their negative controls without
the light-responsive unit were prepared (42–47) (Figure 10). A total of 350 nm irradiation
in PBS efficiently released the parent RuII complexes from the cages within 6–10 min
(1.6–2.6 J/cm2, photorelease quantum yields: 0.4–2.1%), whereas upon irradiation in ACN
no 1O2 production was observed for any of the probes. Cytotoxicity (fluorometric cell
viability assay) and cellular localization (luminescence microscopy) studies were run on
normal MRC-5 (fetal lung fibroblast) and cancerous HeLa cells, either keeping the cells in
the dark following incubation or irradiating them at 350 nm (10 min, 2.6 J/cm2). Under
dark conditions, the free RuII complexes showed no cytotoxicity (IC50 > 100 µM); however,
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two of them showed modest cytotoxicity (IC50 = 65–83 µM) upon light irradiation on HeLa
and MRC-5. Two of the fully armed NLS constructs (42, 43) showed an accumulation
in the nucleus, two NLS constructs showing dark toxicity as well (not increased by UV
irradiation), and overall hardly any selectivity was found for this design. The cellular
localization of BBN-conjugates depended on the RuII-ligands (nucleus/cytoplasm). Two of
the BBN-conjugates showed a light-induced increase in toxicity on HeLa cells; however,
the phototoxic index values were modest (max. 2-fold). The lack of cytotoxicity observed
on MRC-5 cells could be the result of a more efficient uptake into cancerous cells resulting
from the targeting peptide conjugation. Controls without the light-responsive unit showed
no toxicity (neither NLS nor BBN controls). The combination of light activation and cellular
targeting was also studied in the context of ReI complexes (48, 49) [67].




Figure 10. Photoactivatable metal complexes, the PPG indicated in blue. 
Further development led to a photoactivatable Cu-complex with a photolabile nitro-
phenyl group (3GCage; formulated as [CuCl(3Gcage)], Cu3G) (53) [70,71]. UV irradiation 
releases the CuII by cleaving the multidentate chelator backbone (dissociation constant 
0.18 fM at pH 7.4). Complexing the Cu with 3GCage inhibits Cu-induced hydroxyl radical 
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Gasser and coworkers extended photocaging onto a cytotoxic, coordinatively sat-
urated and substitutionally inert RuII complex ([Ru(dppz)2(CppH)]2+ (51)), a ding a
3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl (DMNPB) PPG to a carboxylate necessary for its
activity (50) [68]. The novel probe was sufficiently stable in PBS at 25 ◦C (7% 51 release
over 24 h). UV photolysis (350 nm, in PBS) was studied with UV/VIS and UPLC-MS moni-
toring (20 min, 5.16 J/cm2, ≥92% release, 3.8% quantu yield for photorelease). Cellular
cytotoxicity was assessed on HeLa, U2OS (bone cancer), and MRC-5 (non-cancerous lung
fibroblast) cell lines under dark and light-irradiated conditions (resazurin fluorometric
assay). The caged probe was not cytotoxic till 100 µM over 4 h, whereas light irradia-
tion (350 nm, 10 min, 2.6 J/cm2) efficiently restored the activity (4 h, IC50 (µM), HeLa:
51-dark = 16, 51-UV = 6, 50-UV = 17; U2OS: 51-dark = 30, 51-UV = 13, 50-UV = 17; 48 h, IC50
(µM), MRC-5: 51 = 15, 50 = 85). As a negative control, neither light irradiation itself nor
DMNPB had cytotoxic effects. Of note, 51 itself has photoinduced cytotoxicity contributing
to the final effect due to singlet oxygen production.
Franz and coworkers developed a photocaged PtII complex, wherein the ligand
backbone could be cleaved upon light irradiation (using a nitrophenyl PPG) to allow ligand
exchange and subsequent toxicity ([Pt(cage)]) (52) [69]. Photolysis in pH 7.4 phosphate
buffer onitored with UV/VIS spectroscopy showed a complete conversion in ~2 min
(Φ = 0.75), and with LC-MS, the photoproduct could be identified as the result of two
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bond cleavages. Cytotoxicity was studied in MCF-7 cells in comparison with cisplatin
(LDH release assay). Under dark conditions, cells remained viable following [Pt(cage)]
treatment (up to 200 µM, over 96 h), whereas UV irradiation significantly increased the
cytotoxicity of the probe. However, in control experiments, the ligand backbone itself was
found to be cytotoxic, and this effect was tuned down upon PtII-coordination. Regarding
the mechanism of action, agarose gel electrophoresis did not confirm DNA interactions.
The formation of a charged complex from a neutral one upon photolysis was postulated to
contribute to cell accumulation.
Further development led to a photoactivatable Cu-complex with a photolabile nitro-
phenyl group (3GCage; formulated as [CuCl(3Gcage)], Cu3G) (53) [70,71]. UV irradiation
releases the CuII by cleaving the multidentate chelator backbone (dissociation constant
0.18 fM at pH 7.4). Complexing the Cu with 3GCage inhibits Cu-induced hydroxyl radical
formation, whereas, upon UV photolysis, a 300% increase in hydroxyl radical formation
occurs. To assess whether the reducing cellular environment could lead to CuI release
(in the absence of light), cyclic voltammetry in pH 7.4 PBS buffer was run, giving similar
results as that of the stable Cu(Atsm) bisthiosemicarbazone complex. Further experiments
with various reducing or binding agents in pH 7.4 PBS buffer provided additional in-
dications of stability under most conditions. The cytotoxicity of Cu3G was evaluated
in vitro in MCF-7, HeLa, and HL-60 cancer cells (CellTiter-Blue fluorometric assay). Little
effect on cell viability was observed under dark conditions below 100 µM (IC50~150 µM),
whereas following UV exposure (350 nm, 90 s, conditions sufficient for full conversion)
led to a decreased viability in the different cell lines (IC50~75 µM). H2O2 (non-toxic dose
of 50 µM) had a synergistic effect on cytotoxicity (dark: >80% viability up to 100 µM,
UV: IC50~30 µM). UV irradiation of the 3GCage was well tolerated by the study system
(up to 200 µM), the effect of extracellular copper or the UV irradiation was ruled out by
control experiments. Microscopic studies showed extensive cytoplasmic vacuolization in
light-irradiated Cu3G/Cu3G+H2O2-treated cells, a sign of non-apoptotic cell death. This
pathway could be of interest for treating apoptosis-resistant cell lines.
Metal complexes could serve as caging groups to release organic substrates upon light
irradiation. Bonnet and coworkers described ruthenium complexes ([Ru(tpy)(dmbpy)(L)]2+
and [Ru(tpy)(biq)-(L)]2+) caging a nicotinamide phosphoribosyltransferase (NAMPT) in-
hibitor (STF-31) (54, 55) [72]. The pyridine moiety of the parent drug could coordinate to
ruthenium and could be photodissociated in water (625 nm, photosubstitution quantum
yields: 54: Φ = 0.058 (rt), 0.080 (37 ◦C); 55: Φ = 0.013 (rt), 0.019 (37 ◦C)). Cytotoxicity
was tested on A549, MCF-7, A431, and non-cancerous MRC-5 cell lines under dark and
light-activated (628 nm, 20.6 J/cm2) conditions (SRB assay). For 54 limited difference was
recorded between dark and irradiated samples (phototherapeutic index 0.67–1.3), presum-
ably due to thermal instability. More significant differences were found for complex 55,
with modest cytotoxicity against MRC-5 cells under dark conditions (EC50 = 46 µM) and
increased activity on cancer cells upon irradiation (EC50 = 7.1–19 µM, phototherapeutic
index 1.6–3.6). Given the modest singlet oxygen-producing efficiency of the probes, the
effect was ascribed to the STF-31 released. Indeed, re-running the assays under hypoxic
conditions (1% O2) provided similar results for 55. Light activation was corroborated
also with in vitro NAMPT inhibition assay (55-dark: IC50 = 4.8 µM, 55-lit: IC50 = 0.26 µM,
STF-31: IC50 = 0.25 µM).
2.8. Nitroxide Donors
Depending on the cellular microenvironment, nitric oxide (NO) could exert various
biological functions. NO donors are being studied in the context of carcinogenesis and as po-
tential anticancer agents. Given the various potential effects of NO, a localized action would
be, however, of paramount interest. Hattori and coworkers studied the NIR-triggered
TP release of nitroxide donors (2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical) un-
der air atmosphere (i.e., in the presence of O2) using the 2-(4-nitrophenyl)benzofuran
(NPBF) caging group [73]. One- (365 nm) and two-photon (screening 710–760 nm wave-
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lengths) release of the TEMPO radical was confirmed by electron paramagnetic resonance
(EPR) spectroscopy (OP: 5 mM, 6.0 × 1015 photons/s, 2 probes: 80/56% TEMPO after
10 min/40 s irradiation (in benzene/DMSO) or 81/58% TEMPO after 20 min/40 s irradi-
ation (in benzene/DMSO); TP: 10 mM in benzene, Ti:sapphire laser (pulse width 100 fs,
80 MHz, 700 mW), uncaging efficiency: 1.1 GM (740 nm)/0.22 GM (730 nm)). The cyto-
toxic activity of the released radicals was assessed in vitro in Lewis lung carcinoma (LLC)
cells (trypan blue exclusion assay). With 360 nm light (1 min) vs. unirradiated controls,
an irradiation-length- and cage-concentration-dependent cytotoxic effect was observed
(100 µg/mL: 66.5% (after light irradiation) vs. 87.8% (without light irradiation) living cells).
The role of photochemical radical generation in cytotoxicity was assessed by comparing the
presence of reactive oxygen species (ROS) in irradiated and control samples (ROS-ID oxida-
tive stress detection kit). ROS was detected in cells irradiated in cage-containing medium,
however not in the unirradiated cage-containing samples or the samples irradiated without
the cage. However, the low water solubility of the cages excluded further in vivo assays.
2.9. Thymidylate Synthase Inhibitors
Thymidylate synthase (TS) is a folate-dependent enzyme involved in the synthesis of
2′-deoxythymidine-5′-triphosphate. TS inhibitors are interesting as potential anticancer
agents could be of a folate or nucleotide analog type. 5-Fluorouracil having a TS inhibitory
effect is used in therapy since the 1960s for various GI, breast, and head and neck cancers.
Lin et al. described a porphyrin-drug construct exploiting the tumor-affinity of porphyrins
and using a PPG (an o-nitrobenzyl) for light-triggered drug release [74]. As anticancer
model drug tegafur (a 5-fluorouracil prodrug) was selected, and as a negative control, a
construct with uracil was prepared as well. Photolysis (350 nm) was studied with HPLC
monitoring, showing 50% conversion in 12 min (Φ = 0.032). Cytotoxicity under dark and
UV-irradiated conditions were studied on MCF-7 cells. In 50 µM concentration, tegafur led
to 91% cell death. In the absence of light, the probe was modestly toxic (7% cell death);
however, treatment with pre-irradiated samples led to 67% cell death, such as irradiation
of cells treated with the probe (69% cell death). To ascertain that the cytotoxicity is due
to photorelease and not singlet oxygen formation, a control irradiation experiment with
uracil was run. The observed 6% cell death was comparable to the result obtained with UV
light alone.
2.10. PROTACs (PROteolysis TArgeting Chimeras)
Proteolysis targeting chimeras (PROTACs) emerged recently in the forefront of interest
as a tool for inducing targeted protein degradation. PROTACs are bifunctional molecules
that could facilitate binding between an E3 ligase and a protein of interest, thereby induc-
ing protein degradation via the ubiquitin-proteasome pathway. With PROTACs formerly
not druggable proteins could be addressed as well, including key players of oncogenic
processes. The interest in PROTACs is also underlined by the fact that both photocage
and photoswitch approaches have recently been disclosed [75,76]. Pan and coworkers
developed photocaged PROTACs by linking a DMNB PPG to different positons of dBET1
(comprised of a thalidomide CRBN ligand and a JQ1 BRD4 ligand): either to the amide
nitrogen of the JQ1 unit or the imide nitrogen of the thalidomide unit (56, 57) (Figure 11) [77].
The target protein (BRD4) of dBET1 is a member of the BET (bromodomain and extratermi-
nal) protein family and is acting via super-enhancers and oncogenes expression regulation.
Several clinical studies with small-molecule BET inhibitors were initiated. Photolysis was
studied with HPLC monitoring (365 nm, 3 mW/cm2), showing a rapid conversion of the
probes (t1/2: 57 = 60 s, 56 = 105 s); however, dBET1 release only in the case of 57. Binding
assays confirmed efficient masking of activity upon PPG-linking (BRD4 IC50: 57 = 7.6 µM,
JQ1 = 71 nM, dBET1 = 22 nM). BRD4 degradation was studied in Ramos cells under dark
and UV-irradiated conditions (365 nm, 3 min). Upon light activation, 57 efficiently reduced
BRD4 levels (Dmax = 93% at 1 µM). Antiproliferative activity was studied on Namalwa cells
in comparison with dBET1. UV irradiation could restore 57’s activity to the same range
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as that of dBET1 (57-dark: GI50 = 3.1 µM, 57-lit: GI50 = 0.4 µM, dBET1: GI50 = 0.34 µM).
Long-term effects were studied in HUH7 cells (10-day colony-forming assay), confirming
light-induced activation of 57 (almost complete inhibition at 5 µM vs. no effect on colony
density under dark conditions). In vivo studies were conducted on the zebrafish embryo
model (treatment at 12 h post fertilization, 10 min irradiation at 365 nm or dark conditions),
with DMSO as blank and dBET1 as a positive control. Upon irradiation, 57 led to pheno-
typic changes similar to dBET1 as well as BRD4 degradation confirmed with Western blot
analysis. The effect on BRD4 degradation could be visualized by injecting enhanced green
fluorescent protein-tagged BRD4 into the embryos before treatments. The design strategy
was extended to further targets, namely 58 was prepared in a similar fashion with linking
DMNB to the imide nitrogen of MT-802, a BTK degrader. In Ramos cells, 58 led to BTK
degradation in an irradiation-dependent manner.
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Kounde et al. used an analog d sign for their photocaged PROTAC: a DMNB PPG
attached to a critical OH of the E3 ligase ligand to prevent interaction and a JQ1 pan-
bromodomain warhead connected with a PEG linker (59) [78]. Photocleavage w studied
by UV/VIS and LC-MS monitori g at 365 nm (ACN/H2O 1/1, 50 µM, 25 mW LED), giving
full conversion within 180 s. Cellular activity was assessed on HeLa cells, monitoring
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BRD4 levels with Western blot analysis. Incubation with the caged PROTAC followed by
light irradiation (60 s, 25 mW 365 nm LED) led to dose-dependent protein degradation, not
observed under dark conditions even after a 24 h incubation. Comparing the time frame
of protein degradation between the parent drug and the caged following photorelease,
similar results were obtained (i.e., the uncaging is not a rate-limiting step in the process).
The overall phenotypic effect was tested with live-cell imaging prior to and after light
irradiation on HeLa cells. The caged probe had a cytostatic effect (average proliferation
fold change = 1); however, upon irradiation, similar reduced growth as with the parent
agent could be obtained (average proliferation fold change < 0.5). The former effect is
due to the in-cell target engagement (JQ1-BRD4) of the caged probe. The time course of
light-activated protein degradation was measured by live-cell fluorescence imaging on
HEK293 cells expressing GFP-BRD4, confirming a light-dependent effect for 59.
Deiters and coworkers developed photocaged PROTACs for Von Hippel-Lindau
(VHL) and CRBN E3 ligases [79]. For photoactivatable VHL ligands, the position of the
PPG (a diethylamino coumarin (DEACM)) on the hydroxyproline was selected based
on structural considerations (protein-ligand complex) (60). As a target, estrogen-related
receptor α (ERRα) was chosen for the novel probe. ERRα is a member of the nuclear
receptors superfamily, and its role in various (e.g., breast) cancers was confirmed by several
studies. Photolysis assayed with HPLC and MS monitoring showed a clean release of the
parent PROTAC. To challenge the efficiency of the caging, MCF-7 cells were treated with
the probe under dark or irradiated conditions (365 nm, 3 min), and the ERRα levels were
measured via Western blot analysis (after 8 h). Without irradiation, ERRα PROTAC 60 did
not decrease ERRα levels; however, upon irradiation similar effect was recorded as for the
parent PROTAC. The mechanistic pathway was confirmed with control experiments in the
presence of the proteasome inhibitor MG132 or the neddylation inhibitor MLN4924. For
designing a photocaged CRBN ligand, the PPG (6-nitropiperonyloxymethyl, NPOM) was
linked to the imide moiety of the glutarimide ring (61) of the parent molecule. In addition,
in this case, photorelease was confirmed by HPLC and MS analysis. BRD4 degradation
was studied in HEK293T cells with Western blot analysis. Photocaging efficiently masked
the activity of the parent PROTAC, which could be unleashed with UV irradiation (365 nm,
180 s). The proteasome- and E3-ligase mediated pathway was confirmed with control
experiments with MG132 and MLN4924. To assess the effect of BRD4 degradation, 22Rv1
cells (castration-resistant prostate cancer cell line) were treated with the parent drug (72 h:
51% reduced cell viability) and 61 with and without light activation (61-dark: no significant
effect, 61-lit: 72 h, 39% reduced cell viability). Monitoring caspase-3/7 activation, a similar
effect was observed for the parent drug and light-activated 61.
Liu et al. started their investigations on a parent lead compound: pomalidomide, linked
to a Nvoc PPG to block its binding to E3 ligase CRBN (coined opto-pomalidomide by the
authors) [80]. The attachment point of the PPG at the glutarimide NH was selected based
on structural considerations. Photorelease at 365 nm was confirmed with UPLC-MS and
UV/VIS monitoring (t1/2 = 62 min). Opto-pomalidomide lost in vitro CRBN binding that
could be regained upon 365 nm irradiation (competitive binding assay). Light activation
of opto-pomalidomide intracellularly (on HEK293T cells) was studied via its effect on the
protein-protein interaction between CRBN and IKZF1 (Ikaros zinc finger transcription fac-
tor) and CRBN-dependent IKZF1/3 degradation. The activity of opto-pomalidomide could
be unleashed upon UV irradiation (15 min, no effect without). Exposing opto-pomalidomide
pretreated cells to different lengths of UV irradiation, a light- and drug dose-dependent
IKZF1/3 degradation was recorded (not induced by UV irradiation itself). The effect of
opto-pomalidomide on multiple myelome cells was also light- and CRBN-dependent (dark
conditions vs. 15 min 365 nm irradiation, MM.1S cell proliferation, CCK-8 cell viability
assay). Opto-pomalidomide was used for the synthesis of two light-activatable PROTACs:
opto-dBET1 (62) and opto-dALK (63). Opto-dBET1 lost the parent drug activity (ubiquiti-
nation of BRD2/3) due to caging; however, the effect could be restored intracellularly with
UV light (15 min 365 nm irradiation, HEK293T cells). Subjecting 62 pretreated HEK293FT
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cells to 5 or 15 min UV irradiation, a CRBN and ubiquitin-proteasome system-dependent
BRD3/4 degradation could be operated. While 62 itself is inert, light activation could
offer precision control for avoiding future toxicity issues stemming from complete protein
depletion. A dose-dependent effect of 62 on cell proliferation was recorded (HEK293FT
and C4-2 cells, CCK-8 cell viability assay). The second target, ALK (anaplastic lymphoma
kinase), was selected due to the presence of ALK fusion proteins in several cancer types
(e.g., non-Hodgkin’s lymphoma). As for opto-dBET1, first, the in vitro UV photorelease
of opto-dALK was confirmed (UV/VIS monitoring). Opto-dALK was inactive in ALK
degradation; however, with UV irradiation, a light- and drug dose-dependent EML-ALK
degradation was observed (NCI-H2228 or NCI-3122 non-small cell lung cancer cell lines).
Light activation of 63 also promoted NPM-ALK fusion protein degradation in an anaplastic
large cell lymphoma cell line (SU-DHL-1). While UV irradiation itself did not have a con-
siderable effect, following uncaging 63 reduced the viability of NCI-H2228, NCI-3122, and
SU-DHL-1 cells. Given the sensitivity of SU-DHL-1 cell growth to NPM-ALK degradation,
the cell proliferation effect was more pronounced on this model system.
2.11. Modulators of p53 Signaling
p53 is a central tumor suppressor. Its intracellular level is thoroughly regulated. p53
mutations were identified in several cancers. MDM2 (mouse double minute 2 homolog)
protein acts as a negative regulator of the p53 pathway (via a protein-protein interaction)
and was found to be overexpressed in different cancer cell lines. For selective reactivation
of p53 signaling, Hansen et al. designed a photoactivatable MDM2 inhibitor starting
from idasanutlin and using a coumarine PPG [81]. Based on structural considerations
(SAR and docking studies), the PPG was linked to the m-methoxybenzoic moiety of the
pharmacological agent. Photolysis (400 nm, physiological conditions, 0.1% quantum
yield) cleanly afforded the free idasanutlin, as monitored by UV/VIS and UPLC-MS,
and the construct showed suitable hydrolytic stability. The light-triggered activity of
PPG-idasanutlin was studied on p53-proficient retinal pigment epithelial cells (RPE-1) in
comparison with DMSO control, nutlin-3, and the free idasanutlin with or without 400 nm
light (immunofluorescent staining of nuclear p53 protein levels). PPG-idasanutlin showed
activity only upon light activation (increased p53 level); moreover, a dose-dependent
effect could be attained by varying the duration of the 400 nm light irradiation or the
PPG-idasanutlin dose. The novel probe efficiently blocked the colony outgrowth of RPE-1
cells following exposure to 400 nm light (no similar effect with DMSO+400 nm light control
experiment); however, it had no effect without light irradiation. The scope of the approach
was ascertained on further nontransformed (BJ-hTert) and tumor (RKO, U2OS) cell lines.
Selective activation of PPG-idasanutlin with the single-cell resolution was demonstrated in
a 2D cell culture setup of RPE-1 cells expressing venus-tagged p53. Short (0.1 s) 405 nm
laser pulses of selected regions (5 µm interspaced positions) led to a pharmacological effect
confined to the irradiated areas, as observed by monitoring the cell cycle progression and
quantifying the nuclear p53-venus signal. Diminished effect in neighboring cells (due to
diffusion of the photoreleased active agent) and no effect in unirradiated cells in adjacent
wells were recorded.
3. Photoswitches for Antitumor Applications
As the concept of photocages, that of photoswitches also dates back to several
decades [82], however particularly the recent years have seen a surge of activity in the
field (referred to as photopharmacology) [83,84]. The application of photoswitchable
pharmacological agents is based on their two (or more) interconvertible isomeric forms
that allow significant steric changes upon photoisomerization and, consequently, differ-
ent pharmacological activity. The photoisomerization could proceed via two principal
routes, trans→cis (E→Z) isomerization (e.g., azobenzenes and their heteroaromatic analogs,
indigos, hemithioindigos, stilbenes, hydrazones, and iminothioindoxyls) or 6π electrocy-
clization of a triene system (diarylethenes) [85]. Of further types, spiropyrans, fulgides,
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and donor-acceptor Stenhouse adducts were exploited [86]. Importantly, the photoiso-
merization process is reversible, that is the basic difference vs. photocages. Although the
reversibility confers many advantages, it also adds further layers of complexity. Selective
irradiation is feasible in the case of appropriate band separation, and for further biological
applications, the activation wavelengths should ideally be in the biological window. For
therapeutic applications, the probes should have ideally high photofatigue resistance,
rapid isomerization kinetics, a photostationary state (PSS) sufficiently enriched in the active
isomer, as well as a half-life of the metastable state in line with the planned application.
Depending on the target and the probe’s structure, different scenarios are possible. Both
the thermodynamically more stable (dark) or the less stable (obtained upon light activa-
tion) form could have higher bioactivity. Typically, the sought-for scenario is where the
active form is obtained upon irradiation (i.e., a turn-on activity); thereby, administration
problems could be avoided or background activity resulting from incomplete photoiso-
merization. The active form could isomerize back to the inactive isomer thermally (T-type
photoswitches, thermally reversible) or upon light irradiation (P-type photoswitches, pho-
tochemically reversible), therefore a more localized effect could be obtained, unlike as
for the photocages, where diffusion of the active form from the site of effect might raise
concerns. Besides the optimal photophysical and photochemical properties, the novel
probes should also comply with the criteria of pharmacological/therapeutic applications,
as lack of ground state toxicity, feasible hydrolytic solubility and stability, and resistance
toward reduction in biological media (e.g., by glutathione) [87]. The general strategy for
designing a reversibly activatable drug molecule is either to add a photoswitchable (often
arylazo→“azo-extension”) tag to the pharmacophore of the parent structure or to incorpo-
rate a (often arylazo→“azologization”) photoswitchable unit into the pharmacophore. The
latter strategy could be expected to alter less the overall structure, therefore having less
impact on the pharmacokinetic and pharmacodynamic properties of the parent drug. Evi-
dently, for both approaches besides a clinically validated target, detailed SAR and structural
information are necessary of the target and the parent drug (family). Finally, from a practi-
cal point of view, synthetic accessibility of the novel probes, availability of straightforward
synthetic methods for the desired modifications should also be duly considered.
3.1. Photoswitchable Kinase Inhibitors
One of the first photoswitchable kinase inhibitors, a REarranged during Transfection
(RET) tyrosine kinase inhibitor, was described by Grøtli and coworkers in 2015, based on
an azobenzene-derived pyrazolopyrimidine scaffold and its stilbene counterpart (64–66)
(Figure 12) [88]. The photoswitching properties of the novel probes were studied with
UV/VIS monitoring. The stilbene derivative 64 underwent an irreversible photoreaction
at 302 nm; however, the azobenzene derivatives (65, 66) photoisomerized reversibly (65:
365 nm E→Z, thermal half-life: τ = 2.0 min (37 ◦C); 66: 365 nm E→Z, PSS: 87% Z, thermal
half-life: τ = 9.7 h (37 ◦C), 503 nm Z→E). The probes showed appropriate hydrolytic
stability and resistance to photofatigue upon 10 photoswitching cycles. Assessing in vitro
RET kinase activity under dark and lit conditions (365 nm, 3 min), a dose- and illumination-
dependent effect was recorded (66-E: IC50 = 150 nM, 66-Z: IC50 = 581 nM). The in vitro
results were corroborated by cellular activity assays (66-E: IC50 = 3.8 µM, 66-Z: IC50 = 12 µM)
after ascertaining the irradiation tolerance of the study system (365 nm, 15 min). However,
despite the important proof-of-concept value of the study, for therapeutic applications, the
decrease in activity upon irradiation is generally a less sought-for scenario.
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Peifer and coworke s studied the photoisomerization of the approved (for renal cell
carcinoma) ATP-competitive, type II tyrosine kinase inhibitor axitinib, targeting VEGFR2
(67) [89]. Axitinib has a stilbene-lik moiet in its structure; moreover, instance for its
photoinduced is merization were report . As a starting point to their studies, Peifer and
coworkers examined by molecular modeling the binding modes of the E- and Z isomers of
axitinib in the ATP pocket of VEGFR2. The Z isomer leading t implausible binding modes
upon docking was ssumed to be an inactive form. For furt r studi s, Z-axitinib (67-Z)
wa prep re from E-axitinib (67-E) by 365 nm irradiation; however, the structural analysis
revealed the presenc of two tautomeric (67-Z-1H and 67-Z-2H) forms. Ph toisomerization
and photostationary st tes were stu ied in DMSO and water at differ nt wavelengths by
HPLC- nalysis and 1H NMR (PSS (365 nm) (%) in DMSO: 67-E 40/67-Z 60; PSS (385 nm)
(%) in DMSO: 67-E 78/67-Z 22; PSS (385 nm) (%) in water: 6 -E 96/67-Z 4), showing a re-
versible but incomplete process in DMSO and an irreversible, but complete Z→E pr cess in
water. Axitinib did not sho ignificant p tofatigue in DMSO following several switching
cycles; however, at 365 nm in the water, a competing dimerization occurred (formation of 68,
not observed at 385 nm throughout the Z→E conversion). The two isomers were subjected
to in vitro VEGFR2 kinase assay and selectivity profiling in a panel of 300 kinases, reveal-
ing surprisingly similar IC50 values and selectivity (VEGFR2—67-E: IC50 = 25 nM, 67-Z:
IC50 = 65 nM). Re-running the assays (VEGFR2 and PDGFRβ) under controlled light con-
ditions showed a 43-fold difference between the isomers, as predicted by the Z isomer
being less active. IC50 values were determined in VEGFR2 kinase assay for both isomers
following UV irradiation (Z: 385 nm irradiation, E: 365 nm irradiation). The IC50 observed
upon irradiating the Z isomer (IC50 = 29 nM) suggested an almost complete Z→E con-
version in vitro; however, in the case of the E isomer, a more complex reaction occurred
(IC50 = 44 nM), leading to a mixture containing both isomers and the photodimer product
68 (not active itself in VEGFR2 kinase assay). For cellular studies, a HUVEC (human
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umbilical vein cells) proliferation assay was selected as a model system for angiogenesis.
Dose-response curves were measured in the dark, showing a 31-fold difference between the
isomers (67-E: IC50 = 0.83 µM, 67-Z: IC50 = 26 µM). Irradiating the Z isomer treated cells at
385 nm (after ascertaining the UV-tolerance of the system, 5 min irradiation) led to a similar
inhibition curve to that of the E isomer, therefore suggested an efficient photoswitching.
The difference in activities was further confirmed by Western blot analysis in HUVECS and
NIH/3T3 cells, studying VEGFR2 and AKT phosphorylation. Kinase selectivity profiling of
the two isomers was re-run under controlled light conditions using HUVECs (by PamGene
PamstationR and PamChipR). Besides identifying three eligible target tyrosine kinases for
67-E (FGFR1, RET, SYK), 67-Z was found to act on the relevant kinases with a decreased
intensity. Importantly, the study method used could be an alternative of high-throughput
commercial kinase selectivity screening typically carried out at ambient light conditions,
which might be a serious concern for photoactivatable compounds.
In a follow-up report, the same group set out to prepare azologized versions of axitinib,
incorporating an azobenzene (69–71) or a diazocine unit (72–74) into the parent structure
to solve isomerization reversibility issues [90]. Based on previous results with axitinib,
the E-azoaxitinibe 69 was assumed to be the active form (attaching the azo group directly
to the indazole ring). However, as no photoswitching was observed for the azologized
probe (UV/VIS monitoring) due to fast thermal back-isomerization (due to azo-hydrazone
tautomerization) and also the bioactivity was diminished vs. the parent drug, this design
was dismissed. As a second approach, bistable (sulfur)-diazocine derivatives were de-
signed (72–74), presumably activated upon light irradiation in their E form (backed up by
docking analyses) and compared with two azobenzene derivatives (70, 71). Photochemical
characterization was run in DMSO solution with UV/VIS and 1H NMR monitoring (PSS
(E/Z%)—70: 17/83 (365 nm), 71: 20/80 (385 nm), 72: 47/53 (405 nm), 73: 25/75 (405 nm),
74: 60/40 (405 nm); t1/2 (h), 37 ◦C—70: 43, 71: 5.7, 72: 7.3, 73: 3.7, 74: 1.5). For diazocines,
a lower photoconversion was observed; however, with 530 nm irradiation, a quantita-
tive back-isomerization could be operated. No significant photofatigue was detected till
20 cycles (alternating 20 s irradiation at 405/530 nm), and the half-lives were sufficiently
long for in vitro assays. Bioactivity was assessed first in VEGFR-2 kinase assay under con-
trolled light conditions (IC50 (nM)—69-E: 415, 70-E: 1077, 70-PSS: 1289, 71-E: 1020, 71-PSS:
1435, 72-Z > 10,000, 72-PSS: 214, 73-Z > 10,000, 73-PSS: 251, 74-Z: n/a, 74-PSS: 493). As
expected from the modeling results, the azobenzene derivatives were moderately E active
without significant difference between the isomeric forms. For the diazocine derivatives,
irradiation increased significantly the activity (40–47-fold), even despite the relatively low
E-content of the PSS. Compound 72 was subjected to kinase profiling (PamGene, HUVECs
lysates). Prior irradiation 72 remained inactive, whereas, after irradiation, a moderate effect
was observed. Of note, the water solubility of the novel probes should be further optimized
(necessitating a DMSO-cosolvent for assays).
Szymanski and coworkers developed reversibly photoactivatable BRAFV600E kinase
inhibitors, using an analog of the clinically approved BRAFV600E-selective ATP-competitive
inhibitor vemurafenib as the starting point and an azobenzene photoresponsive unit [91,92].
The parent inhibitor had an amide and a sulfonamide linker, which both might be suitable
for azobenzene replacement. However, studying co-crystal structures of inhibitors binding
BRAFV600E, it was found that the arrangement of the aromatic rings linked by the amide
moiety would resemble more to an E azobenzene isomer endowing it presumably with
higher activity. On the other hand, a bent conformation around the sulfonamide pointed
toward the Z azobenzene isomers being more active. As Z isomers being more potent is
the sought-for scenario for therapeutic uses (allowing an on-demand turn-on activity), the
photoswitch unit was introduced at the sulfonamide. Eight novel derivatives were prepared
with the aim of studying the effect of different substitution patterns on bioactivity and the
main photochemical parameters (main absorption band, rate of thermal relaxation, Z/E
ratio in the PSS). PSS composition was monitored by 1H NMR spectroscopy, appropriately
placed methoxy substituents leading to nearly quantitative photoisomerization (≥88% Z
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at PSS). Z isomer half-lives were monitored in DMSO and BRAF assay buffer/or BRAF
assay buffer-ACN mixture, giving values in the hours range (DMSO: >10–70 h, BRAF
assay buffer/or BRAF assay buffer-ACN: 5 to >24 h). The bioactivity for both isomers
was screened on purified recombinant BRAFV600E, quantifying the phosphorylated-MEK-
1 product with a Western blot to assess the potency vs. the parent compounds and the
difference in activity between the dark and lit states, as well as allowing SAR considerations.
The most promising derivative (75) showed a 10-fold difference of activity between the
two isomers (vemurafenib—IC50 = 9.6 nM, parent inhibitor—IC50 = 22 nM, 75 (dark, E)—
IC50 = 1.7 µM vs. 75 (lit, Z)—156 nM), with a reversible switch of activity upon illumination
and relaxation. These results were in accordance with binding modes obtained upon
docking of the inhibitor into the crystal structure of BRAFV600E. Cellular cytotoxicity assays
were performed on A375 cells (cell viability MTS assay), typically used for BRAFV600E
inhibitors; however, the enzymatic assay activity could not be translated onto this system
(i.e., no activity was observed in neither states). As azologization of a selective kinase
inhibitor might result in a loss of selectivity, the kinome inhibition profile of 75 was recorded
to check for eventual off-target activities potentially explaining the cellular inactivity (on
cell lysates from SK-Mel-28 cells). Increased phosphorylation levels were found compared
to the DMSO control; moreover, 75 has a less favorable PSS ratio (55% Z) that could also be
an important factor of modest cellular performance.
Herges and coworkers reported novel photoswitchable p38α Mitogen-activated pro-
tein kinase (p38α MAPK) and Casein Kinase 1δ (CK1δ) inhibitors [93] and revealed
potential artifacts resulting from pharmacological assay conditions. Using a known
4,5-diarylimidazole inhibitor as the starting point [94], the potential modification site
was designed via docking studies. The 5-membered aromatic ring of the original inhibitor
was designed into the photoswitchable unit; however, to optimize the photoisomerization
process was modified either into a thiazole or an N-methylimidazole ring (Figure 13).
Besides an azobenzene (76, 77), a diazocine photoswitchable unit was tested as well (78), in
the latter case (unlike as for azobenzenes), the Z isomer being thermodynamically more
stable. The docking studies confirmed significant differences in the potential binding of
the E- and Z isomers for both structural types; therefore, a difference in their pharmaco-
logical activities was expected as well. Throughout the photochemical characterization
of the products (in DMSO due to solubility reasons, UV/VIS absorption, photostability,
PSS ratio, and half-lives, alternating isomerization), 76 showed concentration-dependent
photoisomerization (~80% E→Z vs. 29% at 3.5 mM and no conversion at 17 mM, no
concentration-dependence in the 5 µM-100 µM range), that was ascribed to aggregation
effects, as well as an unfavorably short half-life. Compounds 77 and 78 showed no such
concentration dependency (76: PSS—29% Z (435 nm), 81% E (525 nm), t1/2 = 13 min; 77:
85% Z (420 nm), 88% E (525 nm), t1/2 = 2.4 h; 78: 47% E (405 nm), 100% Z (525 nm),
t1/2 = 3.2 d). The pharmacological characterization of the diarylazo products did not con-
firm the expected tendencies, while the diazocine showed no activity (in vitro kinase assay:
CK1δ—76: E (dark) IC50 = 147 nM, PSS (435 nm) IC50 = 55 nM; 77: E (dark) IC50 = 138 nM,
PSS (420 nm) IC50 = 218 nM; 78: not active up to 10 µM; p38α: 76: E (dark) IC50 = 29 nM, PSS
(435 nm) IC50 = 2.4 nM; 77: E (dark) IC50 = 83 nM, PSS (420 nm) IC50 = 115 nM; 78: not active
up to 10 µM). To explain the observed discrepancies, further studies (co-crystallization of
76 in complex with p38 MAPK under ambient conditions, dithiothreitol (DTT) treatment
with NMR monitoring) revealed the formation of a reduced hydrazine product from 76 due
to the DTT present in the assay system. To rule out the effect of the reduction, p38α kinase
assay was re-run without DTT (76-E (dark): IC50 = 67 nM, 76-PSS (435 nm): IC50 = 105 nM),
however CK1δ without GSH could not be performed. Co-crystallization of 76 and 77 with
CK1δ without DTT was performed, confirming the presence of the diazo moiety; however,
no stable conformation was adopted that might explain the modest differences of activity
upon isomerization. As the susceptibility to reduction is structure-dependent (no reduction
observed for 77), it should be duly considered in the design of novel photoswitchable
agents. On the other hand, reducing and stabilizing agents often used in biological assays
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might lead to artifacts, such as ambient light conditions. Further points of consideration
are the aqueous solubility of the compounds and their photophysical properties in aqueous
media (PSS, E/Z half-lives).
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Branda and coworkers studied the design of photoactivatable protein kinase C (PKC) 
inhibitors starting from the bisindolylmaleimide family of ATP-competitive protein ki-
nase inhibitors and using a diarylethene photoswitch scaffold [95]. Protein kinase C 
isoforms are involved in pathways related to the expression of genes affecting cell cycle 
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i i it rs starti fro the bisindolylmaleimide family of ATP-competitive protein ki ase
inhibitors and using a diarylethene photoswitch scaffold [95]. Protein kinase C isoforms
are involved in pathways related to the expression of genes affecting cell cycle progres-
sion, tumorigenesis, and metastatic dissemination. In the studied design, the maleimide
ring of the parent structures with the indole heterocycles at C3 and C4 contains the
1,3,5-hexatriene motif required for the photochemical ring-closing; however, it is not
adopting a photochemically productive conformation. To obtain a photoswitchable ana-
log, one indole was replaced with a thiophene (79). Consequently, the PKC-active form
could rotate into the s-cis-s-cis conformer and undergo cyclization into the PKC-inactive
form (open→closed: 450 nm, PSS: 42% closed form after 7 min irradiation at 50 µM,
0.7 mW/cm2; closed→open: >490 nm). The photoinduced ring-closing reaction was highly
solvent-dependent and not operational in polar solvents (e.g., DMSO, water), the reverse
ring-opening reaction not suffering from these limitations. In vitro activity was studied
on PKC βII (Z’-Lyte assay kit), confirming lack of activity for the ring-closed isomer vs. a
potent activity of the open form (open: IC50 = 580 nM, closed: no measurable dose-response
trend). The activity in the assay could be restored upon light irradiation (buffered solution
of PKC and the closed form in 0.2–25 µM concentration, 30 s irradiation at >490 nm).
3.2. Photoswitchable Epigenetic Modulators
König and coworkers combined a diarylethene photoswitch and a bisindoylmaleimide
pharmacophore to obtain photoactivatable sirtuin inhibitors (3 novel probes: symmetrical
benzothiophene 80 and replacement of one (81) or both benzothiophenes by phenyl substi-
tuted thiophenes (82)) (Figure 14) [96]. Photoswitching at 312 nm was studied in DMSO
(10 µM) with UV and HPLC monitoring (PSS, %: 80—62, 81—87, 82—94), showing a clean
process and resistance to photofatigue (over 5 cycles). In vitro activity against sirtuins was
evaluated in a fluorescent assay (ZMAL) (IC50 (µM), hSirt2—82-open = 4.2, 82-closed = 92;
81-open = 2.3, 81-closed = 2.1; 80-open = 13; 80-closed = 23). Two probes (81, 82) showed
activity in the range of the reference inhibitor Ro31-8220 (IC50 = 0.80 µM); however, for 81,
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no difference between the open and closed forms was registered. Compound 82, however,
besides a 20-fold difference in activity between the open and closed forms, showed also
isotype selectivity toward hSirt1 and hSirt3. The in vitro results were cross-examined with
molecular dockings on human sirtuins. To confirm in situ activation, the closed form was
irradiated under the assay conditions (30 min, 2.5 W, 530 nm), and the time course of the
inhibition was monitored. A constant inhibition was obtained over 20 min, with a value
corresponding to that obtained previously with the open form. The cellular activity of
82 was tested via tubulin hyperacetylation, showing similar tendencies as the Ro31-8220
reference compound.
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Feringa and coworkers studied the design of photoswitchable HDAC inhibitors [97]
using as starting point vorinostat (SAHA), panobinostat, and belinostat (inhibitors approved
for clinical use), and azobenzene as the photoswitch unit. Using structural knowledge
on the parent drug (vorinostat), two molecular designs were envisaged, introducing the
photoswitch either to the cap (83, 84) or the linker region (85, 86). To study their influence
on the photochemical and pharmacological properties, different attachment positions and
substitution patterns on the azobenzene were assessed in the former, whereas different
linker lengths and types in the latter approach. All novel compounds showed appropriate
PSS values (above 75%) upon 365 nm irradiation in DMSO (determined by 1H NMR spec-
troscopy). Depending on the substitution pattern, the half-life of the Z isomer spanned from
the minutes to the hours range (determined by UV/VIS spectroscopy at rt, in HDAC assay
buffer with 1% DMSO), an important property for auto-inactivation upon therapeutical
use. The first screen of activity was performed on class I HDACs (HeLa nuclear extracts),
human recombinant class I HDACs (1–3, 8) and HDAC6. Based on the pharmacological
results, compound 86 was selected for further studies, due to a potent activity of the Z
state (HDAC1 (E): IC50 = 0.66 µM, HDAC1 (Z): IC50 = 0.080 µM; HDAC2 (E): IC50 = 22 µM,
HDAC2 (Z): IC50 = 0.55 µM, HDAC3 (E): IC50 = 0.32 µM, HDAC3 (Z): IC50 = 0.071 µM;
vorinostat: HDAC2—IC50 = 0.18 µM), appropriate Z/E activity ratio and reversible action
upon illumination. Cytotoxicity of selected compounds was measured in a cellular assay
(cell viability of HeLa cells) in both isomeric forms. For 86, in line with the HDAC assays,
the Z isomer showed higher toxicity.
Reis et al. addressed the concept of using photoswitchable small-molecule ligands
with fast equilibrium kinetics and long target residence times in the context of HDAC
inhibitors [98]. For the probe design, the DABCYL fluorescence quencher and known
ortho-anilide HDAC inhibitors (CI-994, Merck C60, MS-275) with a class I HDAC (1–3)
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preference were used as starting points (2 novel probes (87, 88), a control probe and an
HDAC1/2-biased probe were prepared). The expected isomerization-dependent activ-
ity was rationalized with computational studies, as well as structural and SAR infor-
mation. Differential zinc-chelating ability was expected from different electronic prop-
erties rather than resulting from the steric change. Thermal relaxation half-lives were
measured under physiological conditions with microsecond resolution (55–60 µs), how-
ever were expected to still allow subcellular activation vs. diffusion. Light intensity-
(470 nm, Imax = 17 mW/cm2) and concentration-dependent HDAC inhibitory activity
of the novel probes against HDAC1/2/3 were measured. The observed selectivity and
light-dependence of activity were in accordance with the previous design and mechanis-
tic considerations (the authors coined the overall approach “chemo-optical modulation
of epigenetically regulated transcription” (COMET)). Target residence times and dark
phase recovery of enzymatic activity were addressed with different irradiation-dark period
regimes. Cellular activity of the novel probes was measured in MCF-7 cells via acetylation
of histone H3 lysine (H3K9ac) as a marker, confirming a light-dependent action. Histone
H3K9ac levels remained elevated even after 8 h under dark conditions, in line with the
long residence time and prolonged HDAC inhibition of the probes. Spatial control of
activity (<1 mm) was confirmed by differential light exposure of treated MCF-7 cells (dif-
ferential histone H3K9ac depending on light exposure). Slight histone H3K9ac increase
in non-exposed areas was ascribed to suboptimal light-delivery processes. The effect on
the transcriptome was assayed under various experimental conditions (dose, treatment
duration, light exposure) with the L1000 assay method on MCF-7 cells. Expression patterns
observed with 87 under light exposure and CI-994 supported a similar activity. To gain a
further mechanistic insight, network analysis of on- and off-target genes was performed.
3.3. Photoswitchable Antimetabolites
Gorostiza and coworkers studied photoswitching of the human dihydrofolate reduc-
tase (DHFR) inhibitor methotrexate (MTX), selected following stringent chemical-clinical-
(photo)pharmacological criteria [99]. DHFR catalyzes a key step of folate metabolism,
the conversion of dihydrofolate to tetrahydrofolate. Disrupting folate synthesis impairs
thymidine and purine synthesis, consequently the synthesis of DNA, RNA, or proteins,
therefore could reduce cell growth and proliferation. MTX could be used alone or in
combination against, e.g., breast cancer, bladder, or lung cancer. However, MTX is also char-
acterized by serious adverse effects (e.g., ulcerative stomatitis, leukopenia), necessitating
dose reduction or treatment discontinuance. Based on the target binding of methotrexate, a
higher activity for the thermodynamically less stable Z isomer could be expected (docking
studies); moreover, the drug structure is feasible for the azologization approach (Figure 15).
The appropriate site for introducing an azo group was selected based on synthetic and
SAR considerations, i.e., executing tolerated modifications/isosteric replacements. The
presumed activity difference of the isomers was backed up by molecular docking (human
DHFR). The novel analog, called phototrexate by the authors (90), was obtained by isosteric
replacements of the N5 and N8 nitrogens of the pteridine ring and introducing a diazo
bond at C6 of the resulting quinazoline. E→Z photoisomerization could be efficiently
effectuated at 375 nm, Z→E isomerization at 460 nm, without significant photofatigue.
The ratio of the isomers at the photostationary phase was determined by 1H NMR (76%
Z isomer after 375 nm irradiation, 30 min, 4.6 J/cm2, maximal photoconversion could
be achieved with a fluence > 0.6 J/cm2). Thermal Z→E isomerization half-life under
dark conditions was found to be 236 min, phototrexate is a T-type photoswitch (37 ◦C,
aq. solution). Regarding the pharmacological activity, the Z isomer showed a stronger
inhibition effect on DHFR (colorimetric assay), in accordance with the docking results
(Z: 70% inhibition at 10 nM, E: 21% inhibition at 10 nM). In a cellular assay of cytotox-
icity (MTT assay of cell viability, HeLa cells), the same tendencies were observed (Z:
IC50 = 6 nM, E: IC50 = 34 µM). Of note, the difference in pharmacological activity and
efficient in situ photoisomerization was further studied in vivo using zebrafish larvae
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(monitoring viability, anatomical and behavioral traits, comparison at 72 and 96 h post
fertilization) using methotrexate as a positive control. Light-illumination (twice a day with
375 nm light, 0.61 J/cm2, 4 min irradiation) led to a 2- and 8-fold increase in abnormality
and mortality for the Z vs. E isomer (abnormalities at 96 h: E—30%, Z—60%; mortality:
E—6% of the total, Z—46% of total). Minor discrepancies between the activity of the parent
drug and the active Z isomer on the pharmacological assays were ascribed to the different
off-target activity profiles.
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3.4. Photoswitchable PAD Inhibitors 
Protein arginine deiminase (PAD) is involved in the conversion of arginine to citrul-
line. PAD4 was found to be overexpressed in several cancer cell lines (e.g., breast carci-
noma, hepatocellular carcinomas); therefore, a role for altered PAD4 activity in the path-
ogenesis was suggested. Mondal et al. studied photoactivatable PAD inhibitors, using the 
known inhibitor BB-Cl-amidine as their starting point [100]. As BB-Cl-amidine contains a 
biphenyl moiety in its structure, it was assumed that replacing it with a photoswitchable 
azobenzene unit might be a feasible approach. Eight novel derivatives were prepared, 
modifying the amidine warhead and the substitution pattern of the azobenzene to modu-
late the enzyme binding affinity and the PAD isoform-specificity (Figure 16). Photoisom-
erization was studied by UV/VIS spectroscopy, ascertaining the thermal stability of the 
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3.4. Photoswitchable PA Inhibitors
Protein arginine dei inase (PAD) is involved in the conversion of arginine to citrulline.
PAD4 was found to be overexpressed in several cancer cell lines (e.g., breast carcinoma,
hepatocellular carcinomas); therefore, a r le for altered PAD4 activity in the pathogenesis
was suggested. Mondal et al. studied photoactivatable PAD inhibitors, using the k own
inhibitor BB-Cl-amidine as their starting point [100]. As BB-Cl-amidine contai s a biphenyl
moiety in its structure, it was assumed that replacing it with a photoswitchable azobenzen
unit might be a feasible approach. Eight novel deriva ives wer prepared, modifying the
amidine warhe d and the substitution pattern of he azob nzene to m dulat the enzyme
binding affinity and the PAD isoform-specificity (Figure 16). Photoisomerization was tud-
ied by UV/VIS spectroscopy, ascertaining the thermal stability of thermodynamically
less stable Z isomer (compound 91-E: > 12 h half-life) and a fast E→Z conversion upon
irradiation (320–380 nm, 92-E: > 80% conversion after 40–60 s). The E isomer could be
photoconverted back (400–450 nm); however, this process was of less interest as the studied
compounds act as irreversible inhibitors on the target. The bioactivity of the isomers was
assessed in vitro in PAD-inhibition (PAD1-4) assays (COLDER assay). Two promising com-
pounds were identified for photocontrolling PAD-2 activity (implicated in breast cancer).
E→Z isomerization of 91 led to a 10-fold increase in activity, whereas E→Z isomerization
of 92 led to a 45-fold deactivation. For 91, similar results were obtained in a competitive
activity-based protein profiling test (using PAD-targeted rhodamine-conjugated fluoroami-
dine labeling), however similar IC50 values were recorded for the two forms of 92 despite
the previously observed activity difference (91: E IC50 > 100 µM, Z IC50 = 9.1 µM; 92: E
IC50 = 12 µM, Z IC50 = 24 µM). To elucidate this result, further enzyme kinetics studies
suggested 92 to act as a reversible, competitive inhibitor (Ki = 25 µM). Cellular activity was
assessed by studying histone H3 citrullination in HEK293T/PAD2 overexpressing cells.
Upon photoactivation, 91-Z showed a dose-dependent citrullination inhibition activity
(the E isomer showing no activity at 100 µM), whereas 92-E was only marginally active
(~33% inhibition at 100 µM) and its Z-counterpart inactive. Regarding its cytotoxicity on
HEK293T/PAD2 cells, 91 had a similar effect as the parent BB-Cl-amidine, however with
no difference between the Z and E isomers.
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3.5. Microtubule-Targeting Agents 
Small-molecule drugs affecting MT dynamics could exert antimitotic and pro-apop-
totic effects. Combretastatins are potent tubulin binding cytotoxic agents (colchicine do-
main MT inhibitors) of natural origin. They lead to antiangiogenesis and vascular disrup-
tion, resulting in tumor necrosis. Common structural features of combretastatins include 
a trimethoxylated ‘A’-ring, an often C3’ and C4’-substituted ‘B’-ring, and an ethene bridge 
in-between. Clinical trials with combretastatin A4-phosphate targeted, e.g., thyroid or 
ovarian carcinoma. Photoswitchable tubulin polymerization inhibitor combretastatin A4 
(CA4) analogs (coined photostatins by the authors) were addressed by Thorn-Seshold and 
coworkers [101] in their well-documented study. As already for the parent drug, an activ-
ity difference was observed between the E and Z isomer [102]. It was logical to replace the 
central C=C bond with an N=N unit. Besides introducing the N=N unit, analogs with dif-
ferent substitution patterns were prepared (5 probes—e.g., 96), as well as the azobenzene 
analogs of two nonspecific combretastatin prodrugs (e.g., 95) and a hybrid probe with a 
biochemical targeting unit (94). Photoisomerization in PBS with UV/VIS monitoring 
showed a rapid and reversible process, without signs of degradation over hundreds of 
cycles (93: E→Z 388 nm, Z→E 508 nm, τ = 6 min—ranging between 0.8 and 120 min for 
other probes, depending on the substitution pattern). Illumination-dependent cytotoxicity 
was studied in cellular assays in MDA-MB-231 human breast cancer and HeLa cell lines, 
using frequently pulsed, short illuminations vs. dark conditions. The results showed a 
significant (~20–100-fold) increase in activity upon light exposure in both cell lines. Wave-
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uni . Besides introducing the N=N unit, analogs with different substit tion pattern ere pre-
pared (5 probes—e.g., 96), a ell as the zobenzene analogs of two nonspecific combretastatin
prodrugs (e.g., 95) and a hybrid p obe with a biochemical targeti g unit (94). Ph toisomer-
ization in PBS with UV/VIS monitoring showed a rapid and reversible process, without
signs of degradation over hundreds of cycles (93: E→Z 388 nm, Z→E 508 nm, τ = 6 min—
ranging between 0.8 and 120 min for other probes, depending on the substitution pattern).
Illumination-dependent cytotoxicity was studied in cellular assays in MDA-MB-231 human
breast cancer and HeLa cell lines, using frequently pulsed, short illuminations vs. dark condi-
tions. The results showed a significant (~20–100-fold) increase in activity upon light exposure
in both cell lines. Wavelength screening on HeLa cells (MTT assay) pointed toward the con-
centration of the isomer being the principal factor in the bioactivity (i.e., dose-response curves
were in Z correlation with the relative E/Z ratios at the studied wavelengths). Further studies
were conducted with 93 and its prodrug 95 in MDA-MB-231 cells, assaying cell membrane
permeability (propidium iodide exclusion assay) and nuclear fragmentation (quantification
of DNA content). A light-induced effect was observed in both cases, also corroborated by
results gathered in Jurkat (T cell lymphoma) and HeLa cells (G2/M arrest: 93-Z—500 nM,
93-E—> 100 µM). Of note, using a rescue lighting regime (390 nm pulses alternating with a
515 nm pulse) decreasing the 93-Z concentration effectively led to a reduced G2/M arrest
(vs. normal cell cycle repartition under dark conditions). Examining PARP-cleavage (Western
blot, HeLa cells), the PARP proteolytic signature typical of apoptosis was observed only after
light-illumination. In an in vitro radioligand scintillation proximity assay, the competitive
displacement of 3H-colchicine by 93 from its tubulin binding site was measured. For 93-Z
(390 nm), an EC50 = 30 µM was found, whereas the 93-E showed no significant competitive
binding to tubulin. In vitro tubulin polymerization inhibition was observed under 390 nm in
a dose-dependent manner (EC50~5 µM vs. EC50(dark) >> 40 µM). Under 390 nm illumination
regime, 93 led to dose-dependent microtubule depolymerization in cellulo vs. no effect under
dark conditions (immunofluorescence imaging of endogenous tubulin). By imaging the end-
binding protein EB3 (total number of EB3 comets, lifetime, speed, distance traveled), direct
visualization of microtubule dynamics in live cells was undertaken while photoswitching 93 in
situ (alternating 2 min phases of pulsed 405 nm and 514 nm light). Importantly, optical control
over microtubule dynamics could be achieved with 93 also in vivo (mitotic progression of
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developing C. elegans embryo, ms pulses of 405 and/or 514 nm light) with single-cell preci-
sion. In mammalian tissue in vivo (cremaster muscle tissue of living mice), 93 illuminated at
390 nm had disruptive effects on the microtubule network that was not detected under dark
conditions. Streu and coworkers used the same design for their [103] azo-combretastatin A4
(93) (i.e., central C=C to N=N) (Figure 17). Photoisomerization in CDCl3 (10 mM) with 1H
NMR monitoring showed a maximum ~9/1 Z/E ratio under 10 min (400 nm LED flashlight).
Photoisomerization at lower concentration was studied by UV/VIS monitoring (400 nm LED
flashlight, 30 µM in DMSO, the maximum ratio reached in <10 s). The effect on tubulin
polymerization in vitro was studied by turbidity assay. Under dark conditions (E), no activity
was detected; however, the activity could be switched on upon light exposure (Z). Cytotox-
icity of azo-combretastatin was studied in HeLa cells (MTT assay) under dark conditions
(EC50 > 100 µM) and in the presence of light (10 s irradiation every 30 min with 400 nm
LED flashlight; complete cell death at 0.5 µM), showing a more than 200-fold increase upon
illumination. Parallelly, the light irradiation tolerance of the study system and CA4 was
ascertained in control experiments. Azo-combretastatin (Azo-CA4—93) was also character-
ized by Hartman and coworkers [104]. Photoswitching was studied by UV/VIS, 380 nm
irradiation (4.4 mW/cm2), providing the Z isomer in 30 s. The half-life was recorded in
various solvents to rule out their effect, as longer periods than the previously described
values were recorded, even under identical conditions (0.25% DMSO in H2O: 100 min,
0.25% DMSO in PBS: 88 min, 0.9% DMSO in PBS: 75 min, 10% ACN in PBS: 92 min,
20% ACN in PBS: 85 min). Alternating photoswitching and relaxation cycles could be
operated over 24 h without significant degradation. In vitro inhibition of tubulin poly-
merization was studied in a fluorescent assay under dark and lit (pre-activated—380 nm,
4.4 mW/cm2, 1 min) conditions, showing a 2.8-fold difference between the isomers (93-Z:
IC50 = 5.1 µM, CA4: IC50 = 1.9 µM). Cytotoxicity was assayed in HUVECs and MDA-MB-231
cell lines, using different illumination regimes. EC50 values ascertained a light activation and
were in correlation with the pulse frequency, i.e., the concentration of the Z isomer (93-Z:
EC50(MDA-MB-231) = 0.6 µM, EC50(HUVEC) = 0.4 µM; 93-E: EC50(MDA-MB-231) = 21 µM,
EC50(HUVEC) = 9.5 µM; CA4: EC50(MDA-MB-231) = 0.0021 µM, EC50(HUVEC) = 0.4 µM).
As light irradiation did not restore the total activity of CA4, the stability of 93 toward GSH
was studied. Both isomers degraded in the presence of GSH over the course of hours, leading
to the formation of rearrangement and GSH-adduct products (LC-MS monitoring).
Brittain and coworkers set out to prepare a library of novel azo-combretastatins [105].
A total of 17 probes were prepared, with different (O-alkyl) substituents on the B-ring,
applying previous SAR knowledge pointing toward alcohol or amine at the 3-positon being
advantageous. Except for 4 para-phenol derivatives with extremely fast thermal relaxation,
the other probes reached E→Z PSS within 3–7 min upon UV irradiation. Cell viability was
screened on HeLa and H157 (lung cancer) cell lines (MTT assay) under dark and irradiated
conditions (390–400 nm, 10 s pulse every 34 min). Of the 17 novel azo-combretastatins,
11 showed activity; however, significant light-dependence was observed for 3 probes with
up to a 550-fold difference in activity. To obtain a better insight into the operation of 97,
tubulin binding was studied with ligand binding simulations; however, no significant
difference was found compared to reference compound 93. As another possible factor in
bioactivity, aqueous solubility was studied [106]. Compound 97 is slightly less soluble than
93, with a modest difference in Z/E solubility. Potential contribution to the effect of the
longer Z half-life was also considered (1H NMR, water: 93—46 h, 97—138 h).
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Tho n-Seshold and coworkers dedicated further studies to ph toswitchable microtubule-
targeting agents, with the aim of providing novel photoactivatable scaffolds (C=C bond
based styrylbenzothiazoles—SBTs) to circumvent challenges with the broadly used azoben-
zenes (e.g., overlap of isomerization and assay imaging readout wavelengths, N=N re-
duction in cellular environments, suboptimal relaxation half-lives) [107]. Two novel CA4
analog probes (98, 99) and their functional group permutation variants as negative controls
were designed (coined SBTubs by the authors). The novel probes had no absorbance above
450 nm, showed convenient photoisomerization at 360 nm (PSS: ~85% Z), and suitable pho-
toresistance under aerobic aqueous conditions. Thermal relaxation at 50–60 ◦C proceeded
overnight (b ck photoisomerization unfe sible du to band overlap), theref re in a cellular
context, E→Z sw tching could be envisaged. Of note, SBTubs ph toswitching also operated
with tw -photon excitation (780 nm). Photo- a d biochem cal stabil ty of he novel probes
was ascertained by subjecting them to continuous high-power UV irradiation and GSH
challenge assays, and preliminary metabolic assessment was performed (metabolism by
liver microsomes, cytochrome inhibition, hERG binding). Light-dependent cellular antipro-
liferative effects were tested on HeLa cells (pulsed illuminations with 360 or 420 nm light,
or dark conditions, 75 ms per 15 s, <1 mW/cm2; ~1–2 µM IC50 (~85% Z) vs. > > 20 µM
IC50 (~100% E), no light-dependent activity for the negative controls). Mechanism of action
was verified by inhibition of tubulin polymerization assay, target X-ray co-crystallization
studies (Z-specific tubulin binding at the colchicine site), and imaging the MT network
archit cture in SBTub-treated cells (360 nm light). The latter showed similar dose epen-
dency as the viabili y studies as well s a typical pattern of MT-inhibiti g antimitotics
(specificity corroborated with permutation variants and light-dependent G2/M phase cell
cycle arrest for Z-SBTubs). Further conceptual studies were conducted with the better
performing 99. Notably, single isomerization in situ (18 s 360 nm low-power LED) resulted
in a similar antiproliferative effect as that after repeated irradiations. In situ photocontrol
(405 nm pulse) of MT dynamics could be operated orthogonally with GFP-EB3 (488 nm)
or YFP-EB3 (514 nm) imaging. Temporal reversibility of the effect on MT dynamics was
demonstrated by an EB3-GPF imaging assay, and its scope was extended to a further setup
(A549 cell line).
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To develop an alternative photoswitch unit, where Z- and E-bioactivities on the same
target might straightforwardly be interchanged on demand by structural modifications de-
pending on the planned application, Thorn-Seshold and coworkers studied hemithioindigo
derivatives [108,109] in the context of microtubule-targeting antimitotic agents. Due to the
breadth of available structural knowledge, the colchicinoid pharmacophore was selected
as starting point. As between the pharmacophoric trimethoxyphenyl and methoxyphenyl
rings, several types of linkers might be tolerated. The hemithioindigo unit was embedded
into the bridge while keeping the colchicinoid substitution pattern to avoid loss of activ-
ity. Due to structural and synthetic considerations, four study structures were prepared
(100–103), as well as three negative controls lacking specific on-target activity according to
SAR considerations (having a modified substitution pattern) to rule out nonspecific effects
in biological assays (novel probes coined “HOTubs” by the authors). Due to solubility
reasons, photocharacterizations were conducted in a PBS/DMSO 25/75 mixture (450 nm
irradiation giving the highest PSS content of the E isomer (65%), 530 nm irradiation the
highest PSS content of the Z isomer (97%) –103, t1/2 = 30 min). The photoswitching was
found to be repeatable (over 285 cycles) and reversible even in non-degassed solutions. Cel-
lular antiproliferative activity was assayed on HeLa cells (MTT assay), applying a repeated
illumination regime to keep a PSS equilibrium. Of the four novel derivatives, three showed
feasible activity, and in line with the design reasonings, both dark-active and lit-active
probes were obtained (lit-dark EC50 ratios ranging from 0.5 to 4.0). Importantly, the nega-
tive controls showed decreased and illumination-independent toxicity, suggesting cellular
tolerability of the hemithioindigo structures. For gaining mechanistic insight into bioac-
tivity, further studies were conducted. The effect on tubulin polymerization was assessed
by immunofluorescence staining and confocal microscopy of the polymer microtubule
network of the cells after extended treatment (24 h), confirming an illumination-dependent
effect. Cell cycle repartition was assessed by flow cytometry, showing a G2/M cell cycle
arrest typical of the pharmacological class in a dose- and illumination-dependent manner.
In a follow-up study, further optimizations of hemithioindigo probes were addressed to
improve the bioactivity while keeping the beneficial photochemical properties [110]. To this
end, the substitution pattern was rationally designed, using a colchicine domain inhibitor
indanocine scaffold as a starting point. A small set of novel probes with a para-methoxy
group vs. the sulfur was prepared (coined HITubs by the authors) to allow subsequent
SAR considerations. Compound 104 showed reversible photoswitching in polar aprotic
solvents (Z→E 450 nm (~70% E), E→Z 530 nm (~97% Z)), a thermal half-life of ~40 s, and
high fatigue resistance. Regardless of the pH, no photoswitching was detected in aqueous
solution. Cellular studies were pursued, however, due to the expected biolocalization of
the probes in cellular lipid environments. Cellular activity was assayed with resazurin
antiproliferation assay on HeLa cells, the best performing probe showing an enhanced
effect vs. previously disclosed HOTubs (104: EC50 dark (Z) = 0.11 µM, EC50 450 nm
(E) = 0.45 µM). To gain an insight into the mechanism, tubulin polymerization inhibition in
a cell-free assay was addressed, giving an effect in the same range as that of colchicine for
104. The effect on the cellular MT network was studied with immunofluorescence staining
with confocal microscopy, showing a light-dependent action. Cell cycle repartition was
studied by flow cytometry (propidium iodide incorporation), giving a further indication of
tubulin binding.
In the realm of microtubule-stabilizing probes, with an aim to extend the potential
biological applications (vs. microtubule destabilizers), Thorn-Seshold and coworkers de-
veloped photoswitchable PTX-based agents (coined “AzTax” by the authors) [111]. Based
on structural and SAR considerations, the photoswitch unit (an azobenzene) was intro-
duced at the 3’-amine so as to tune down the potency of PTX besides offering a substantial
difference of activity between the isomers. Two structural factors were examined: the
orientation of the azobenzene (ortho, meta, or para vs. the amide) affecting potency and
substitution of the distal azobenzene aromatic ring affecting photochemistry. For the
most potent series, further azobenzene substitution patterns were tested as well to check
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their effect on isomer potencies and solubility. Due to solubility reasons, photoswitch-
ing studies were conducted on diethanolamide models in aqueous media (PBS with <1%
DMSO) (unsubstituted compounds: (PSS) 375 nm—80% Z, 410 nm—26% Z; τ~50 days;
methoxylated compounds: (PSS) 375 nm—96% Z, 530 nm—11% Z; τ~24 h) with UV/VIS
monitoring. Quantitative E→Z isomerization could be operated with overnight 60 ◦C
heating of DMSO stock solutions. Para-amino compounds featured no observable photo-
switching in aqueous conditions; however, in moderately polar environments (EtOAc),
a reversible isomerization could be detected ((PSS) 410 nm—91% Z, 530 nm—21% Z;
τ~11 min). Structure- and light-dependent cytotoxicity was assayed in HeLa cells (re-
sazurin cell proliferation/viability assay) under dark or UV conditions. The best per-
forming agent (105) was characterized with a 6-fold dark(all-E)/lit(mostly Z) EC50 ratio
(EC50(dark) = 1.4 µM, EC50(360 nm) = 0.24 µM). Mechanism of action of 105 was further
addressed in tubulin polymerization cell-free assays and studying the effect of the in situ
irradiated probe on the cellular MT network (immunofluorescence imaging) and cell cycle
repartition (flow cytometry). Spatiotemporal control over the activity with single-cell preci-
sion was demonstrated on HeLa cells expressing a fluorescent reporter (EB3-tdTomato) for
polymerizing MTs (1 µM 105, low-intensity 405 nm irradiation).
As a further antimitotic approach, targeting microtubule-associated motor proteins
could be envisaged. In this respect, Tamaoki and coworkers designed a photoswitchable
version for the selective centromere-associated protein E (CENP-E; kinesin-7) inhibitor
GSK923295 (under clinical trials) disrupting the alignment of chromosomes
during mitosis [112].
3.6. Photoswitchable F-Actin Modulating Agents
The migratory ability of cancer cells is critical for invading the adjacent tissues and the
vasculature and for subsequent metastasis formation. In cell migration processes, cellular
actin filaments and the actin cytoskeleton play a crucial role; therefore, the anticancer
potential of cytoskeletal filament-directed agents is being studied (complementary to
microtubule-based agents). Arndt and coworkers used a natural F-actin stabilizing product,
jasplakinolide, as the starting point for their studies on the design of photoactivatable agents
(coined optojasps by the authors) affecting the actine cytoskeleton [113]. Jasplakinolide
was modified by an azobenzene photoswitch unit using an “azo-extension” approach. A
set of eight different probes was designed, with varying amino acid side chain lengths and
connection geometry of the photoswitch, besides a judicious selection of the azobenzene
substitution pattern (targeting bidirectional photoswitching, appropriate solubility, and
actin-selectivity). The novel probes showed efficient photoswitching (PSS: ~10:1 Z/E),
appropriate thermal relaxation half-lives, with its range depending on the connection
type (ACN, 25 ◦C: ortho: ~36 h, para: ~80 min; aq. buffer, 37 ◦C: ortho: ~200–250 min,
para: ~18 min) and photostability (>12 h pulsed irradiations with 390 and 450 nm light).
Light-dependent cellular cytotoxicity was assessed on HeLa cells. Optojasp-1 was found to
be Z-active (EC50 (µM): E > 15, Z = 1.5) and was characterized in further studies. (Of note,
E-active probes were identified as well among the novel optojasps). Regarding its effect on
the cellular actin cytoskeleton (fluorescence microscopy), optojasp-1 led light-dependently
(at 390 nm) to similar cellular phenotypes as that observed with known F-actin stabilizers,
without affecting the MT network. With back-isomerization (475 nm irradiation) followed
by dark incubation, the regular actin cytoskeleton could be phenotypically recovered.
Target-selectivity (rate of F-actin polymerization) and lack of nonspecific interactions (due
to solubility or aggregation issues) were ascertained. With optojasp-1, cell motility could
be reduced in a light- and dose-dependent manner, and photocontrol over the completion
of cell division could be achieved as well. The spatiotemporal control over cytoskeletal
MRTF-A signaling was demonstrated in single-cell irradiation experiments.
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3.7. Photoswitchable Metal Complexes
Gamez and coworkers designed photoswitchable platinum(II) complexes with a 1,2-
dithienylethene unit in the ligand, with the aim of achieving distinct DNA-interacting and
cytotoxic properties in the two isomeric forms (Figure 18) [114]. Two ligands were prepared
with different substitution patterns on the central ring (H or F—106, 107). Photoswitching
of the novel ligands and the platinum complexes were studied by UV/VIS, indicating a
reversible photocyclization. The closed forms were stable under dark conditions; however,
they showed partial opening under daylight (24 h, in DCM solution, UV/VIS monitoring).
DNA interactions were assessed by competitive binding studies (ct-DNA, ethidium bro-
mide, fluorescence spectroscopy), and the DNA affinity of the complexes was quantified by
the respective Stern–Volmer quenching constants. The closed forms showed an increased
level of DNA interactions. The interaction with pBR322 DNA was studied by agarose
gel electrophoresis, indicating significantly different behavior for the open and closed
forms. Cell viability was studied on six cancer cell lines (A549 (lung adenocarcinoma),
A375 (melanoma), DMS53 (small cell lung cancer, SCLC), GLC4 (SCLC), MCF7 (breast
adenocarcinoma), PC3 (prostate adenocarcinoma)), first by a single-point assay with 50 µM
complex. Complex 106 showed mostly >75% viability values both in the open and the
closed form, with no significant differences between the isomers. For complex 107, the
open form had a modest effect (74–95%), whereas the closed form showed cytotoxicity
on five of the studied cell lines (all except A549, 16–79%), together with a distinguishable
activity of the isomeric forms (e.g., SCLC DMS53: 74% (open) vs. 29% (closed)). The single-
point assay results were corroborated also by the determined IC50 values (48 h, 106-open:
IC50 = 77 µM, 106-closed: IC50 = 76 µM, 107-open: IC50 = 76 µM, 107-closed: IC50 = 34 µM,
cisplatin: IC50 = 8.53 µM). Exploiting the fluorescence of the complexes, cellular uptake was
studied by confocal microscopy on four cell lines (affected—A375, DMS53, unaffected—
PC3, A549). The results showed an efficient uptake for both complexes, however different
staining in correlation with the cytotoxic properties.
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In a follow-up study, Gamez and coworkers revisited the design of photoactivatable
platinum(II) complexes using dithienylcyclopentene-based ligands, where light-induced
changes occur in the coordinated ligand instead of the me al center itself [115]. Photoswitch-
ing of the ligands was characterized by UV/VIS and 1H NMR before pursuing platination.
The interaction of the closed and open form of the novel complexes with pBR322 DNA was
assayed by agarose gel electrophoresis, showing a structure- and concentration-dependent
effect. Most of the closed isomers showed a DNA-unwinding ability, ascribed to insertion
of the complexes and binding of the platinum atoms. In competitive binding studies
(fluorescent intercalator—ethidium bromide—displacement assay), the closed forms had
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an increased quenching effect, therefore a better intercalating activity. Calculating the
Stern–Volmer quenching constants, similar tendencies (open vs. closed forms) were ob-
served for all the complexes studied. Cellular activity of the complexes was assessed
on five cell lines: lung adenocarcinoma (A549), A375, MCF7, colorectal adenocarcinoma
(SW620), and ovarian adenocarcinoma (SKOV3). Modest cytotoxic activities were detected
in most cases (10 and 50 µM, above 75% survival), with no difference between the open
and closed forms, except for the closed form of complex 108 and the open form of the
photochemically inert (i.e., not cyclizable) complex 110 (108-open: IC50(A375) > 75 µM,
IC50(SW620) > 75 µM; 108-closed: IC50(A375) = 3.1 µM, IC50(SW620) = 2.4 µM; 110:
IC50(A375) = 3.4 µM, IC50(SW620) = 1.8 µM vs. cisplatin: IC50(A375) = 6.6 µM,
IC50(SW620) = 13 µM). In the latter case, a different mode of action (vs. the other studied
complexes) was assumed, which was confirmed by circular dichroism analysis of the
interaction of the complexes with ct-DNA.
3.8. Photoswitchable Proteasome Inhibitors
Proteasome inhibition via one/more active catalytic sites hampers the degradation
of superfluous proteins (including abnormal and misfolded proteins) and could prevent
the degradation of pro-apoptotic factors, on the other hand. The first in class bortezomib
was approved in 2003 for multiple myeloma and mantle cell lymphoma. Its adverse
effects include peripheral neuropathy and myelosuppression. Feringa and coworkers
prepared photoswitchable proteasome inhibitors by adding an azobenzene unit to the
peptidic part of the approved inhibitor bortezomib, based on structural and SAR information
(Figure 19) [116]. The planar E form was expected to retain activity vs. the bent Z form.
Photoisomerization and half-lives of the Z isomers were studied by UV and 1H NMR in
DMSO-d6/D2O and H2O solutions (Z% upon irradiation: 72–90%, except 112; half-life
37 ◦C (h): ~4–8 h). Reversible photoswitching (at least four cycles) was observed for all
novel probes, also under reducing physiological conditions (111 (20 µM), PBS (10 mM),
pH 7.4, GSH (10 mM)). The biological activity of the inhibitors was studied in competition
experiments on cell lysates before and after irradiation (365 nm). In accordance with the
previous reasonings, activity was decreased upon irradiation (β1: 1.4–2.2-fold difference,
β1i: 1.9–2.9-fold difference), with similar trends at β1 and β1i and a less pronounced
difference on β5. Moreover, depending on the substitution pattern, differential activity and
specificity for effect on active sites could be tuned. Cellular cytotoxicity assays were run
on HeLa cells (MTT assay), showing between samples before and after irradiation (15 nm,
365 nm) minor differences in the IC50 values rather than in the curve shapes.
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3.9. Photoswitchable PROTACs 
The design of photoactivatable PROTACs was investigated by several groups. The 
construct of Reynders et al. consisted of a ligand for an E3 ubiquitin ligase (binding to the 
CRL4CRBN complex), a photoswitch unit, and a ligand targeting BET family proteins 
(BRD2,3,4) or FKBP12. As CRBN ligands pomalidomide and lenalidomide were considered, 
whereas as photoswitchable linker either a conventional azobenzene or a diazocine (Fig-
ure 20) [118]. The first set of probes was prepared using a (+)-JQ1 ligand, which is an in-
hibitor of BRD2,3,4 and BRDT (13 novel probes, studying different substitution patterns 
and linker lengths). A second series targeting FKBP12 consisted of a CRBN-targeting glu-
tarimide, an azobenzene photoswitch, a linker, and a synthetic ligand for FKBP12 (SLF) (6 
novel probes studying different positions of the photoswitch). The lead compound of the 
first series (115) had >90% Z isomer in the PSS (390 nm), reverse isomerization at >450 nm 
providing >70% E form (thermal half-life (37 °C, DMSO): 8.8 h). The effect on cell viability 
was studied on RS4;11 lymphoblast cells under dark and light-irradiated conditions (100 
ms 390 nm pulse every 10 s), confirming an increased cytotoxicity upon light irradiation 
(115: EC50 = 88 nM (390 nm), EC50 = 631 nM (dark)). Targeted protein (BRD2-4) degradation 
in RS4;11 cells was studied by Western blot analysis under dark and light conditions with 
increasing concentrations of 115, also confirmed in MB-MDA-231 and MB-MDA-468 cell 
lines. Light irradiation led to a decrease in BRD4 and BRD3 levels (100 nM–3 µM, higher 
. t it l , .
Blanco et al. also used the known agents bortezomib and delanzomib as starting
points [117]. In one series, different azobenzenes were assessed at the site interacting
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with the P2 pocket of the target (bortezomib analogs 113), whereas in a second series,
different azobenzenes were introduced at the N-terminus (delanzomib analogs 114). Pho-
toisomerization and PSS composition were studied with 1H NMR in DMSO-d6 solutions,
showing significantly Z-enriched states upon irradiation (365 nm, 1 h) for most of the
novel probes (Z%: 83–89 bortezomib analogs, 46–92 delanzomib analogs). In vitro activity
was evaluated against β5 and β1 proteasome subunits in comparison with the parent
drugs. Structural modifications were typically well tolerated; however, the highest dif-
ference observed upon irradiation was around 5-fold (decrease in activity). 113, having
the highest β5 activity besides a 5-fold difference between the isomeric states, was sub-
jected to further cellular toxicity studies on HCT-116 colon colorectal and MDA-MB-468
breast carcinoma cell lines (7AAD assays). In cellular studies a reversal of activity was ob-
served compared to the proteasome subunit assays (113-E: LD50(HCT-116) = 1.0 µM, 113-Z:
LD50(HCT-116) = 0.21 µM; 113-E: LD50(MDA-MB-468) = 0.25 µM, 113-Z:
LD50(HCT-116) = 0.14 µM), 113-Z showing modest cytotoxicity also on non-malignant
MCF-10A cells, while the 113-E tested inactive (till 5 µM).
3.9. Photoswitchable PROTACs
The design of photoactivatable PROTACs was investigated by several groups. The
construct of Reynders et al. consisted of a ligand for an E3 ubiquitin ligase (binding to
the CRL4CRBN complex), a photoswitch unit, and a ligand targeting BET family proteins
(BRD2,3,4) or FKBP12. As CRBN ligands pomalidomide and lenalidomide were consid-
ered, whereas as photoswitchable linker either a conventional azobenzene or a diazocine
(Figure 20) [118]. The first set of probes was prepared using a (+)-JQ1 ligand, which is an
inhibitor of BRD2,3,4 and BRDT (13 novel probes, studying different substitution patterns
and linker lengths). A second series targeting FKBP12 consisted of a CRBN-targeting
glutarimide, an azobenzene photoswitch, a linker, and a synthetic ligand for FKBP12 (SLF)
(6 novel probes studying different positions of the photoswitch). The lead compound of the
first series (115) had >90% Z isomer in the PSS (390 nm), reverse isomerization at >450 nm
providing >70% E form (thermal half-life (37 ◦C, DMSO): 8.8 h). The effect on cell viability
was studied on RS4;11 lymphoblast cells under dark and light-irradiated conditions (100 ms
390 nm pulse every 10 s), confirming an increased cytotoxicity upon light irradiation (115:
EC50 = 88 nM (390 nm), EC50 = 631 nM (dark)). Targeted protein (BRD2-4) degradation
in RS4; 11 cells was studied by Western blot analysis under dark and light conditions
with increasing concentrations of 115, also confirmed in MB-MDA-231 and MB-MDA-468
cell lines. Light irradiation led to a decrease in BRD4 and BRD3 levels (100 nM–3 µM,
higher concentrations: hook effect), not observed in the dark. A less pronounced effect
was detected for BRD2. Further mechanistic studies confirmed the mode of operation of
the novel probe (co-treatment with the CRL inhibitor MLN4924 fixing BRD2-4 levels upon
irradiation, study following siRNA knockdown of CRBN, study following the methyla-
tion of glutarimide, effect on c-MYC levels, rescue experiment with thermal relaxation
or optical inactivation, wavelength dependence of the effect). Time dependence of the
BRD2-4 degradation and c-MYC down-regulation was assessed over 24 h. Following pulse
irradiation also led to an increased rate of PARP-1 cleavage. Of the second series, 116 and
117 were selected for biological testing on RS4;11 cells. A light-dependent effect on FKBP12
degradation was observed, with a slower onset than for BRD2-4 (no protein between 6 and
12 h). The modular design approach of the studied probes could be a valuable starting
point for the development of future photoactivatable PROTACs.
Carreira and coworkers used the BET-degrader ARV-771 (JQ-1 ligand for BRD4, VHL
ligand for E3 ligase) as their starting point, designing a bistable, photoswitchable ortho-
tetrafluoroazobenzene into the linker region (as a “pull-pull” diacid), the length of which
is critical for activity (118) [119]. Based on structural considerations, the Z isomer was
expected to exert protein degrader activity (i.e., have optimal distance between the war-
head ligands). The photoisomerization in DMSO at 415 nm led to a PSS with 95% E
isomer (ΦZE(415 nm) = 0.65), the reverse process at 530 nm to a PSS with 68% Z isomer
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(ΦEZ(530 nm) = 0.28). No thermal isomerization of the Z isomer was observed over days in
DMSO, ACN, or aq. buffer at 37 ◦C (i.e., the system is indeed bistable) and the probe was
stable in the presence of glutathione (50 µM probe, 10 mM reduced glutathione, 3 days) and
in cells as well (LC-MS analyses of cell lysates). Biological activity was tested on Ramos
cells, with pre-irradiated (415 or 530 nm, 30 min) solutions of 118. 118-E led to BRD2
degradation in nanomolar concentration (6.5 h incubation), which was not detected for
118-Z in the same range. Time-dependent degradation profiles (1–24 h) were recorded for
the two isomers, showing an onset of effect for 118-E at 3 h, reaching a maximum at 7 h and
remaining constant in the following 17 h despite the single irradiation protocol. To ascertain
the mechanism of action (proteasomal pathway), experiments with the NEDD8 inhibitor
MLN-4924 were run. Interestingly, no significant degradation of BRD4 was observed,
which points toward an altered selectivity profile vs. the parent ARV-771. To challenge the
reversibility of the photoswitching, experiments with a two-step irradiation regime were
run (single irradiation of 405 or 530 nm vs. two-step 405–530 or 530–405 nm irradiation),
showing a reversal of activity after double irradiation. A similar reversal was obtained
upon incubation of E-treated cells under 530 nm or Z-treated cells under 403 nm irradiation
vs. dark conditions.
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Jin et al. designed a photoactivatable PROTAC targeting BCR-ABL (implicated in
chronic myelogenous leukemia) [120]. As E3 ligase ligand lenalidomide was used and
the attachment point for the photoswitchable azobenzene unit was selected based on
structural analysis (CRBN and lenalidomide complex X-ray structure). On the other side
of the construct, the tyrosine kinase inhibitor dasatinib was conjugated. Upon assembly
of the fully armed construct, different linker lengths were tested, compound 119 show-
ing the best target protein degrading activity. Photoswitching was studied in DMSO
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solution (361 nm and white light, thermal half-life (25 ◦C, DMSO): 10.3 h), and stabil-
ity against GSH reduction was ascertained as well. Cellular effects and selectivity were
studied on BCR-ABL- (K562, cell proliferation assay—IC50 = 68 nm, cell viability assay—
EC50 = 28 nm) vs. non-BCR-ABL-driven cell lines (A549, HCT116, MCF-7, HEK293T),
showing a differential activity toward the BCR-ABL-driven cell line. The mechanism
of action (CRBN-dependent ABL degradation) of compound 119 was examined in con-
trol experiments in the presence of dasatinib, an N-methylated version of compound 119,
lenalidomide, or MLN4924 (NEDD8-activating enzyme inhibitor). BCR-ABL degradation
studies of the separate E and Z isomers confirmed a significant difference in activity, in
line with previous structural analysis results (E: degradation of BCR-ABL and ABL at
100 nM, >90% BCR-ABL degradation after 32 h; Z: no BCR-ABL degradation till 500 nm,
no reduction in BCR-ABL until 32 h), whereas ABL gene expression was not affected. The
reversibility of action upon light irradiation following treatment with 119-E was studied
on K562 cells upon UVC irradiation regime vs. white light (VIS) conditions. BCR-ABL and
ABL protein levels remained low in the VIS group vs. the UV-irradiated cells. On the other
hand, 119-Z treatment followed by VIS exposure also led to BCR-ABL degradation.
3.10. Photoswitchable Peptidomimetics
Synthetically modified peptides are opening novel avenues in chemical biology and
medicinal chemistry and are a prime target for photopharmacology [121]. Albert et al.
studied peptidomimetic photoswitchable histone methyltransferase inhibitors, targeting
MLL1—an enzyme implicated in certain acute leukemias and solid tumors [122]. Komarov
and coworkers prepared a photoswitchable derivative of the cyclic peptide gramicidin S
(GS), using a diarylethene scaffold connected via a keto group (120, 121) (Figure 21) [123].
In vitro cytotoxicity of the open and closed forms (121) was tested on HeLa, COLO-25
(colorectal cancer), and healthy MAEC (BALB/c mouse aortic endothelial) cell lines (MTT
assay). The open form had IC50 values close to the parent GS (~6 µM) and a 5.5–8.0-fold
higher cytotoxicity compared to the closed form. To move toward in vivo models, photoac-
tivation in situ was planned, for which the irradiation conditions (wavelength, intensity)
were determined in model tissues, trying to find an optimal compromise between photoiso-
merization efficiency, tissue penetration, and irradiation tolerability. As well, pharmacoki-
netic parameters were studied to ascertain stability (37 ◦C, human blood serum, 16 h) and
reaching appropriate tumor tissue concentrations. For the latter, a mice model with Lewis
lung carcinoma allograft was used. After intraperitoneal administration (5 mg/kg, single
dose) of the closed form, blood and tumor tissues from sacrificed animals were studied
by HPLC (different time points till 2 h). The highest blood concentration was reached in
less than 15 min and maintained over 2 h, accompanied by an accumulation in the tumor
tissue. Under dark conditions, over the 2 h period, less than 5–10% open form was detected
in the blood samples. Upon VIS irradiation of the tumor areas (570 nm, 550 mW/cm2,
10–20 min), >75% close→open isomerization was observed, without significant change of
the concentration of the open form in the blood (<12% conversion). In vivo antitumor effect
was evaluated with the LLC model in C56B1/6 mice, with seven groups (8 animals/each)
receiving daily i.p. injection of the vehicle (EtOH/saline 1/10), GS (1 mg/kg or 9.1 mg/kg)
or the closed 121 (1.0 mg/kg or 9.1 mg/kg). 121-treated groups were subjected to local VIS
irradiation (100 mW/cm2, 15 min after injection) and compared with the unirradiated 121
treated control groups. Photo-treatment improved by 60% the survival compared to the
control group, and post-mortem analysis revealed decreased and necrotic tumor tissues
(~20 days).
Important in vivo information on the safety of photoswitchable anticancer peptides
(121 and its single-point mutants (LMB033, LMB037, LMB039, and LMB040) and their
parent drug, gramicidin S) was obtained in a follow-up study by Komarov and cowork-
ers [124]. The study peptides had a diarylethene photoswitch unit, therefore two thermally
stable forms (open and closed, isomerization wavelengths: 325 and 653 nm). In previ-
ous studies, 121 had phototherapeutic index values (HC50 of the closed isomer (human
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erythrocytes) vs. IC50 of the open isomer) in the 8–11 range on different cancer cell lines,
and the toxicity of its open form was similar to that of the parent drug, GS. To compare
safety data, the LD50 values were determined in C57BL/6 for GS and both isomers of 121
as an indication of acute toxicity. The obtained results (LD50 (mg/kg)—121-open = 19,
121-closed = 29, GS = 18) showed a decreased toxicity for the closed form upon IV adminis-
tration (Cremophor EL/physiological saline 5/95 formulations); however, the difference
was significantly lower than that observed in vitro (~1.5 vs. 20-fold). For a better under-
standing of the toxicity results, the pharmacokinetic parameters of the 121 isomers were
measured in C57BL/6 mice. High plasma concentrations and slow clearance rates were
observed, partly due to high plasma protein binding. Moreover, 121 had high metabolic
stability under physiological conditions (blood plasma, microsomal). Both isomers had a
significant inhibitory effect on CYP450 enzymes at 10 µM concentration. The distribution
of the isomers following photoactivation was studied as a potential source of toxicity. The
concentration of the isomers was measured in blood and tumor tissue samples prior to and
after light irradiation (i.v.-administered 121-closed mice with engrafted LLC), and a control
experiment without irradiation was run. Following irradiation, the concentration of the
open form increased in the tumor tissues but was not significant in the blood plasma. Of
potential nonspecific interactions, hERG inhibition was assessed, showing an alarmingly
high effect. To obtain peptides with more beneficial safety profiles, novel analogs were
prepared and evaluated (LMB033, LMB037, LMB039, AND LMB040, structures not dis-
closed). High cytotoxicity was observed for the open forms on a series of human cancer cell
lines and some interesting differences of activity (closed/open), particularly for LMB033
(17.5–60-fold). LMB033 and LMB040 had lower hemolytic activity as well, which translated
to higher in vivo LD50 values in C57BL/6 mice (LD50 (mg/kg): 20–48). For LMB040, i.p.
administration was less toxic than the i.v. route, which confirmed that the suboptimal
pharmacokinetic parameters could be a reason for toxicity. As phototoxicity is a major
concern for future therapeutic applications, LMB040 was tested in this sense on Balb/c
mice. Following i.p. administration at high dose, the toxicity data of animals kept under
normal daylight vs. in darkness was compared. The signs of toxicity observed underline
the importance of tackling this issue in future development projects. Overall, despite an
increased safety vs. the parent drug, in vitro assays were not sufficiently predictive for
in vivo toxicity. On the other hand, efficient local activation with light could be achieved,
and it did not lead to a rapid redistribution of the active isomer.
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4. Challenges and Future Perspectives
Reversible or irreversible photoactivatable anticancer agents should comply with
a plethora of photophysical, photochemical, pharmacokinetic, and pharmac dynamic
criteria. For their successful developm t, contributions from distinct scientific fields
are n cessary, which might often b difficult with the present e ucational infrastructure,
aca emic frameworks, and mindset. Many of the challenges that externally address-
able drug delivery systems face are also relevant for the field of light-responsive rug
molecules. Hoare and coworkers, in their study, identified tissue penetration, delivery
to and retention at the active site, control over activation signal in vivo, materials and
instrumentation complexity and translational models, and safety as the main issues to
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be addressed to facilitate translation toward therapeutic applications [125]. The wave-
length required for the photoactivation and consequently the tissue penetration of the
light trigger indeed is a bottleneck of future in vivo light-controlled approaches. In this
respect, probes operating at higher wavelengths (red, infrared) or ideally in the biological
window (λ = 650–1450 nm) [126] would be advantageous, and many efforts have been
dedicated to developing such photoactivatable units of a specific design. In the field of
azobenzene photoswitches, longer wavelength absorption generally leads also to faster
thermal relaxation; moreover, the relative stabilities of the Z and E isomers could be altered
as well. A typical approach for shifting the absorption toward higher wavelengths is to
prepare push-pull systems with appropriately positioned electron-donating and electron-
withdrawing groups (e.g., in certain azo dyes [127]). Not all structural modifications
leading to higher wavelength absorption are feasible for photoswitches if they lead to a
construct beyond the drug-like size or to a high number of rotatable bonds. In their 2015
account, Wooley and coworkers collected possible alternatives for the development of
long-wavelength azobenzene photoswitches for in vivo applications [128]. For obtaining
small-molecule azo-photoswitches with red-shifted absorption and slow (s/min) thermal
relaxation in water, altering judiciously the substitution pattern might be a straightforward
route. In this respect ortho-amino/fluoro [129] and tetra-ortho-methoxy/chloro/thioether
substitutions were studied [130–133]. Moreover, azonium ions formed from variously
methoxy-substituted derivatives showed interesting absorption properties as well [134].
Absorption could be shifted into the visible range with Lewis acid coordination of the azo
group’s n-electrons (e.g., BF2) [135,136]. Diazocines (bridged azobenzenes) offer complete
switching in both directions, a red-shifted absorbance, and a thermal relaxation rate in
the minutes range [137,138]. However, due to the cyclic structure, the Z isomer is the
more stable one, which is typically the less sought-for option. Hecht and coworkers re-
ported a one-photon, strong donor-acceptor-based dihydropyrene photoswitch showing
nearly quantitative (95%) isomerization at >800 nm [139]. In the field of photocages, ex-
amples of probes operating at long wavelengths, e.g., boron dipyrromethene (BODIPY) or
heptamethine cyanine derivatives, could be cited [140–144].
Photoisomerization and photocleavage might profit from two-photon absorption that
necessitates the use of femtosecond pulsed laser systems. This might be feasible by using
specifically designed probes. Two-photon absorption (TPA) is a nonlinear optical process.
The simultaneous absorption of two low-energy photons (occurring only at high light
intensity) leads to photoreaction. Especially in the field of photocages, a wide variety of
two-photon activatable probes are available, and work is continuously in progress for
further derivatives with improved photophysical and photochemical profiles [145,146].
Dipolar TPA probes typically have electron-donating/acceptor groups attached to a central
core by conjugated systems. Lengthening the conjugated system or altering the properties,
positioning of substituents are general design principles, as well as preparing more complex
constructs [147]. Next to modifications of the chromophore, specific formulations could
also allow harnessing longer wavelength light, e.g., the use of upconverting nanoparticles
or alternative sources of light, as the Cherenkov radiation (i.e., internal co-localization of
the light source and the photoactive agent) [148].
Although a number of in vivo experiments on multicellular organisms are discussed
in the above sections, typically, reports disclosing photoactivatable probes are based on
in vitro assays (proof-of-concept studies). For future therapeutic applications, it would be
highly needed to gain a better insight into how these systems could be operated under
in vivo conditions. The most studied in vivo application of photoactivatable agents so far
is vision restoration, a logical choice regarding the site of activation [149]. However, it
demonstrates the applicability of the concept per se. For targeting tumors in deeper tissues,
further obstacles still need to be overcome. Regarding in vivo photochemistry, Wooley and
coworkers developed a fluorescence reporter to monitor in situ azobenzene photoswitching
(in zebrafish, over 2 days) [150]. Feringa and coworkers classified potential therapeutic
interventions from the point of view of how light-accessible the different organs are [151].
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To reach deeper tissues, instrumentation developed for diagnostic purposes or PDT therapy
could be exploited [152].
Besides releasing the active (form of the) drug, specifically designed photoactivatable
systems could have further features. Notably, as also illustrated by some examples in
the previous sections, photoresponsive probes could also offer in situ monitoring of the
drug release (i.e., rational dosimetry). Typically for photocages, release or formation of
a fluorescent species is a general approach for real-time monitoring of the photorelease.
Particularly when moving toward in vivo systems, getting quantitative information on
free drug concentration has tremendous practical importance. Particularly in the realm of
nanodevices, light-triggered action could be complemented with imaging modalities (i.e.,
theranostic construct designs) [153–155].
On-target activity requirements for photocages and photoswitches differ substantially.
Photocages rely absolutely on the activity of the released compound, i.e., native ligand,
which is usually a clinically used drug. Photocaging approach, however, also offers a
possibility to use more potent (toxic) compounds, which cannot be used directly due to
side effects or unsuitable physicochemical and pharmacokinetic properties. Additionally,
the introduction of PPGs enables tuning drug-likeness of the prodrug. As PPGs must fulfill
many requirements, there are not available PPGs with robust properties, which would
allow for tuning fine properties (solubility, permeability, etc.) of photocaged compounds.
This is a substantially unexplored area, which might offer significant improvements in the
coming years. The on-target activity of photoswitches is a considerably more demanding
task. Usually, photoswitchable moieties are relatively big and might substantially impair
intrinsic binding. Nevertheless, the herein presented structures demonstrate that it is a
feasible task. At this point, photoswitchable PROTACs are specific and successful examples
offering a general approach to locating photoswitchable moieties as linker units or locating
photoswitchable moieties on E3 ligase recruiting ligand and not interfering with the protein
recruiting part.
5. Conclusions
Photocaging and photoswitching are known approaches as alternatives in the discov-
ery of novel anticancer compounds. As the discovery of anticancer compounds (or novel
APIs themselves) is a highly demanding task, adding another level of complexity raises
several further concerns, such as regulatory issues, different pharmacokinetic properties of
the isomers, the dependence of the photochemical properties on the environment to name
just a few. Therefore, it makes it fully understandable that many reports at present are com-
ing from academic groups describing the idea and very basic implementation. Currently,
we are in the phase where the concept is being developed on the level of compounds and is
focused on optimizing compound properties, while biological activity is mainly validated
with cancer cell line assays. Rapid development and constantly improved compounds are
leading researchers into the stage that compounds will be evaluated in animal models,
and proposed improvements in anticancer therapy will be thus validated. There are still
many potentials for novel concepts to be explored, and photocaging and photoswitching
are undoubtedly some of the most exciting areas of anticancer research.
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